Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2014

01-03-2014 | NON-THEMATIC REVIEW

Platelets and cancer: a casual or causal relationship: revisited

Authors: David G. Menter, Stephanie C. Tucker, Scott Kopetz, Anil K. Sood, John D. Crissman, Kenneth V. Honn

Published in: Cancer and Metastasis Reviews | Issue 1/2014

Login to get access

Abstract

Human platelets arise as subcellular fragments of megakaryocytes in bone marrow. The physiologic demand, presence of disease such as cancer, or drug effects can regulate the production circulating platelets. Platelet biology is essential to hemostasis, vascular integrity, angiogenesis, inflammation, innate immunity, wound healing, and cancer biology. The most critical biological platelet response is serving as “First Responders” during the wounding process. The exposure of extracellular matrix proteins and intracellular components occurs after wounding. Numerous platelet receptors recognize matrix proteins that trigger platelet activation, adhesion, aggregation, and stabilization. Once activated, platelets change shape and degranulate to release growth factors and bioactive lipids into the blood stream. This cyclic process recruits and aggregates platelets along with thrombogenesis. This process facilitates wound closure or can recognize circulating pathologic bodies. Cancer cell entry into the blood stream triggers platelet-mediated recognition and is amplified by cell surface receptors, cellular products, extracellular factors, and immune cells. In some cases, these interactions suppress immune recognition and elimination of cancer cells or promote arrest at the endothelium, or entrapment in the microvasculature, and survival. This supports survival and spread of cancer cells and the establishment of secondary lesions to serve as important targets for prevention and therapy.
Literature
1.
Honn, K. V., Tang, D. G., & Crissman, J. D. (1992). Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Reviews, 11(3–4), 325–351.PubMed
2.
Rados, C. (2004). Beyond bloodletting: FDA gives leeches a medical makeover. FDA Consumer, 38(5), 9.PubMed
3.
Winkel, R., Tajsic, N., Husum, H., Schlageter, M., Hanebuth, G., & Hoffmann, R. (2013). Saphenous perforator flap. Operative Orthopädie und Traumatologie, 25(2), 152–161.PubMed
4.
5.
Steinhubl, S. R. (2011). Historical observations on the discovery of platelets, platelet function testing and the first antiplatelet agent. Current Drug Targets, 12(12), 1792–1804.PubMed
6.
Addison, W. (1842). On the colourless corpuscles and on the molecules and cytoblasts in the blood. London Med Gaz, 30, 144–152.
7.
Schultze, M. (1865). Ein heizbarer Objecttisch und seine Verwendung bei Untersuchungen des Blutes. Arch Mikrosc Anatomy, 1, 1–42.
8.
Bizzozero, J. (1882). Über einen neuen Formbestandtheil des Blutes und dessen Rolle bei der Thrombose und der Blutgerinnung. Virchows Archiv für pathologische Anatomie und Physiologie und für klinische Medizin, 90, 261–332.
9.
de Gaetano, G. (2001). A new blood corpuscle: an impossible interview with Giulio Bizzozero. Thrombosis and Haemostasis, 86(4), 973–979.PubMed
10.
Virchow, R. (1856). Gesammelte (ad) Handlungen zur wissenschaftlichen Medizin. Frankfurt Meidinger.
11.
Bizzozero, G. (1869). Sul midollo delle ossa. Napoli: Tipografia Italiana.
12.
Osler, W., & Schäfer, E. A. (1873). über einige im Blute vorhandene bacterienbildende Massen. Centralbl Medicine Wissensch, 11, 577–578.
13.
Howell, W. H. (1890). Observations upon the occurrence, structure, and function of the giant cells of the marrow. Journal of Morphology, 4, 117–130.
14.
Wright, J. H. (1906). The origin and nature of the blood plates. Boston Medical and Surgical Journal, 23, 643–645.
15.
Wright, J. H. (1910). The histogenesis of blood platelets. Journal of Morphology, 21, 263–278.
16.
Nakeff, A., & Maat, B. (1974). Separation of megakaryocytes from mouse bone marrow by velocity sedimentation. Blood, 43(4), 591–595.PubMed
17.
Pease, D. C. (1956). An electron microscopic study of red bone marrow. Blood, 11(6), 501–526.PubMed
18.
Trousseau, A. (1865). Phlegmasia alba dolens. Lectures on clinical medicine. Delivered at the Hotel-Dieu, Paris, 5, 281–332.
19.
Bariety, M. (1947). Trousseau, 1801–1867 (pp. 234–235). Geneva: Mazenod.
20.
Osler, W., & McCrae, T. (1900). Latent cancer of the stomach. Phil Medical Journal, 5, 245.
21.
Sproul, E. (1938). Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body and tail of the pancreas with multiple venous thrombosis. American Journal of Cancer, 34, 566–585.
22.
Edwards, E. (1949). Migratory thrombophlebitis associated with carcinoma. The New England Journal of Medicine, 240, 1131–1135.
23.
Gross, F. B., Jr., Jaehning, D. G., & Coker, W. G. (1951). The association of migratory thrombophlebitis with carcinoma. North Carolina Medical Journal, 12(3), 97–101.PubMed
24.
Henderson, P. H., Jr. (1955). Multiple migratory thrombophlebitis associated with ovarian carcinoma. American Journal of Obstetrics and Gynecology, 70(2), 452–453.PubMed
25.
Jain, S., Harris, J., & Ware, J. (2010). Platelets: linking hemostasis and cancer. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(12), 2362–2367.PubMedPubMedCentral
26.
Jarniou, A. P., & Moreau, A. (1959). Recurrent & migratory thrombophlebitis revealing a secondary cancer with mediastino-pulmonary form. Presse Médicale, 67(27), 1117–1118.PubMed
27.
Jennings, W., & Russel, W. (1948). Phlebothrombosis associated with mucin-producing carcinomas of the tail and body of the pancreas. Archives of Surgery, 56, 186–198.PubMed
28.
Kenney, W. (1943). The association of carcinoma in the body and tail of the pancreas with multiple venous thrombi. Surgery, 14, 600–609.
29.
Linquette, M., Mesmacque, R., Fossati, P., Luez, G., & Beghin, B. (1964). Recurrent and migratory venous thromboses. Prog ress in Medical (Paris), 92, 689–698.
30.
Mainoli, S., & Piccinelli, O. (1956). Migratory thrombophlebitis and malignant tumors; migratory thrombophlebitis occurring during two cases of reticulosarcoma. La Riforma Medica, 70(46), 1330–1334.PubMed
31.
McKay, D., & Wahle, G. (1955). Disseminated thrombosis in colon cancer. Cancer, 8, 970–978.PubMed
32.
Noble, S., & Pasi, J. (2010). Epidemiology and pathophysiology of cancer-associated thrombosis. British Journal of Cancer, 102(Suppl 1), S2–9.PubMedPubMedCentral
33.
Nusbacher, J. (1964). Migratory venous thrombosis and cancer. New York State Journal of Medicine, 64, 2166–2173.PubMed
34.
Oster, M. W. (1976). Thrombophlebitis and cancer. A review. Angiology, 27(10), 557–567.PubMed
35.
Picard, R., Horeau, J., Guillon, J., & Robin, C. (1959). Migratory thrombophlebitis & bronchopulmonary cancer. Bulletins et Mémoires de la Société Médicale des Hôpitaux de Paris, 75(9–11), 327–329.PubMed
36.
Popesco, I., & Ciobanu, V. (1958). Migratory thrombophlebitis as a manifestation of visceral cancer. La Semaine des Hôpitaux, 34(1), 26–30.PubMed
37.
Rizzo, J. A. (1956). Migratory thrombophlebitis and visceral cancer. Revista de la Asociación Médica Argentina, 70(825–826), 236–238.PubMed
38.
39.
Womack, W. S., & Castellano, C. J. (1952). Migratory thrombophlebitis associated with ovarian carcinoma. American Journal of Obstetrics and Gynecology, 63(2), 467–469.PubMed
40.
Pineo, G. F., Regoeczi, E., Hatton, M. W., & Brain, M. C. (1973). The activation of coagulation by extracts of mucus: a possible pathway of intravascular coagulation accompanying adenocarcinomas. The Journal of Laboratory and Clinical Medicine, 82(2), 255–266.PubMed
41.
Brugarolas, A., Elias, E. G., Takita, H., Mink, I. B., Mittelman, A., & Ambrus, J. L. (1973). Blood coagulation and fibrinolysis in patients with carcinoma of the lung. Journal of Medicine, 4(2), 96–105.PubMed
42.
Peterson, H. I., Appelgren, K. L., & Rosengren, B. H. (1969). Fibrinogen metabolism in experimental tumours. European Journal of Cancer, 5(6), 535–542.PubMed
43.
Peterson, H. I., Appelgren, K. L., & Rosengren, B. H. (1972). Experimental studies on the mechanisms of fibrinogen uptake in a rat tumour. European Journal of Cancer, 8(6), 677–681.PubMed
44.
Peterson, H. I., & Zettergren, L. (1970). Thromboplastic and fibrinolytic properties of three transplantable rat tumours. Acta Chirurgica Scandinavica, 136(5), 365–368.PubMed
45.
Moolten, S. E., & Vroman, L. (1949). The adhesiveness of blood platelets in thromboembolism and hemorrhagic disorders; measurement of platelet adhesiveness by the glass-wool filter. American Journal of Clinical Pathology, 19(8), 701–709.PubMed
46.
Levin, J., & Conley, C. L. (1964). Thrombocytosis associated with malignant disease. Archives of Internal Medicine, 114, 497–500.PubMed
47.
Gasic, G. J., Gasic, T. B., Galanti, N., Johnson, T., & Murphy, S. (1973). Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease. International Journal of Cancer, 11(3), 704–718.
48.
Gasic, G. J., Gasic, T. B., & Stewart, C. C. (1968). Antimetastatic effects associated with platelet reduction. Proceedings of the National Academy of Sciences of the United States of America, 61(1), 46–52.PubMedPubMedCentral
49.
Gastpar, H. (1973). Inhibition of “cancer cell stickiness” through bencylan-hydrogen fumarate (fluditate). Fortschritte der Medizin, 91(33), 1322–1328.PubMed
50.
Hilgard, P. (1973). The role of blood platelets in experimental metastases. British Journal of Cancer, 28(5), 429–435.PubMedPubMedCentral
51.
Warren, B. A. (1973). Environment of the blood-borne tumor embolus adherent to vessel wall. Journal of Medicine, 4(3), 150–177.PubMed
52.
Warren, B. A., & Vales, O. (1972). The adhesion of thromboplastic tumour emboli to vessel walls in vivo. British Journal of Experimental Pathology, 53(3), 301–313.PubMedPubMedCentral
53.
Cliffton, E. E., & Grossi, C. E. (1956). Effect of human plasmin on the toxic effects and growth of blood borne metastatis of the Brown-Pearce carcinoma and the V2 carcinoma of rabbit. Cancer, 9(6), 1147–1152.PubMed
54.
Johnson, J. H., & Woods, J. R. (1963). An in vitro study of fibrinolytic agents on V2 carcinoma cells and intravascular thrombi in rabbits. Bulletin of the Johns Hopkins Hospital, 113, 335–346.PubMed
55.
Pearce, L., & Brown, W. H. (1923). Studies based on a malignant tumor of the rabbit: V. Metastases. Part 1. Description of the lesions with especial reference to their occurrence and distribution. The Journal of Experimental Medicine, 38(4), 347–366.PubMedPubMedCentral
56.
Rous, P., & Kidd, J. G. (1938). The carcinogenic effect of a papilloma virus on the tarred skin of rabbits: I. Description of the phenomenon. The Journal of Experimental Medicine, 67(3), 399–428.PubMedPubMedCentral
57.
Woods, J. R. (1964). Experimental studies of the intravascular dissemination of ascitic V2 carcinoma cells in the rabbit, with special reference to fibrinogen and fibrinolytic agents. Bulletin der Schweizerischen Akademie der Medizinischen Wissenschaften, 20, 92–121.PubMed
58.
Fidler, I. J. (1970). Metastasis: quantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2′-deoxyuridine. Journal of the National Cancer Institute, 45(4), 773–782.PubMed
59.
Honn, K. V., Menter, D., Cavanaugh, P. G., Neagos, G., Moilanen, D., Taylor, J. D., et al. (1983). A review of prostaglandins and the treatment of tumor metastasis. Acta Clinica Belgica, 38(1), 53–67.PubMed
60.
Honn, K. V., Bockman, R. S., & Marnett, L. J. (1981). Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins, 21(5), 833–864.PubMed
61.
Menter, D., Dunn, J., Palazzo, R., Tchen, T., Taylor, J., & Honn, K. (1982). Tumor cell induced platelet aggregation: inhibition by prostacyclin, thromboxane A2 and phosphodiesterase inhibitors. In: Prostaglandins and cancer. New York: Alan R. Liss.
62.
Menter, D. G., Harkins, C., Onoda, J., Riorden, W., Sloane, B. F., Taylor, J. D., et al. (1987). Inhibition of tumor cell induced platelet aggregation by prostacyclin and carbacyclin: an ultrastructural study. Invasion & Metastasis, 7(2), 109–128.
63.
Menter, D. G., Onoda, J. M., Taylor, J. D., & Honn, K. V. (1984). Effects of prostacyclin on tumor cell-induced platelet aggregation. Cancer Research, 44(2), 450–456.PubMed
64.
Cavanaugh, P. G., Sloane, B. F., Bajkowski, A. S., Gasic, G. J., Gasic, T. B., & Honn, K. V. (1983). Involvement of a cathepsin B-like cysteine proteinase in platelet aggregation induced by tumor cells and their shed membrane vesicles. Clinical & Experimental Metastasis, 1(4), 297–307.
65.
Crissman, J. D., Hatfield, J., Schaldenbrand, M., Sloane, B. F., & Honn, K. V. (1985). Arrest and extravasation of B16 amelanotic melanoma in murine lungs. A light and electron microscopic study. Laboratory Investigation, 53(4), 470–478.PubMed
66.
Crissman, J. D., Hatfield, J. S., & Honn, K. V. (1986). Clinical and experimental morphologic parameters predictive of tumor metastasis. Progress in Clinical and Biological Research, 212, 251–267.PubMed
67.
Crissman, J. D., Hatfield, J. S., Menter, D. G., Sloane, B., & Honn, K. V. (1988). Morphological study of the interaction of intravascular tumor cells with endothelial cells and subendothelial matrix. Cancer Research, 48(14), 4065–4072.PubMed
68.
Kinjo, M. (1978). Lodgement and extravasation of tumour cells in blood-borne metastasis: an electron microscope study. British Journal of Cancer, 38(2), 293–301.PubMedPubMedCentral
69.
Machlus, K. R., & Italiano, J. E., Jr. (2013). The incredible journey: from megakaryocyte development to platelet formation. The Journal of Cell Biology, 201(6), 785–796.PubMedPubMedCentral
70.
Menter, D. G., Hatfield, J. S., Harkins, C., Sloane, B. F., Taylor, J. D., Crissman, J. D., et al. (1987). Tumor cell-platelet interactions in vitro and their relationship to in vivo arrest of hematogenously circulating tumor cells. Clinical & Experimental Metastasis, 5(1), 65–78.
71.
Sloane, B. F., Rozhin, J., Hatfield, J. S., Crissman, J. D., & Honn, K. V. (1987). Plasma membrane-associated cysteine proteinases in human and animal tumors. Experimental Cell Biology, 55(4), 209–224.PubMed
72.
White, J. G. (1967). A simple method for preservation of fine structure in blood cells. Thrombosis et Diathesis Haemorrhagica, 18(3–4), 745–753.PubMed
73.
White, J. G., & Krivit, W. (1967). The canalicular system of blood platelets: apossible sarcoplasmic reticulum. The Journal of Laboratory and Clinical Medicine, 49, 60.
74.
White, J. G., & Krivit, W. (1967). Changes in platelet microtubules and granules during early clot development. Thrombosis et Diathesis Haemorrhagica. Supplementum, 26, 29–42.PubMed
75.
Grossi, I. M., Fitzgerald, L. A., Kendall, A., Taylor, J. D., Sloane, B. F., & Honn, K. V. (1987). Inhibition of human tumor cell induced platelet aggregation by antibodies to platelet glycoproteins Ib and IIb/IIIa. Proceedings of the Society for Experimental Biology and Medicine, 186(3), 378–383.PubMed
76.
Bluteau, D., Lordier, L., Di Stefano, A., Chang, Y., Raslova, H., Debili, N., et al. (2009). Regulation of megakaryocyte maturation and platelet formation. Journal of Thrombosis and Haemostasis, 7(Suppl 1), 227–234.PubMed
77.
78.
79.
McGrath, K., & Palis, J. (2008). Ontogeny of erythropoiesis in the mammalian embryo. Current Topics in Developmental Biology, 82, 1–22.PubMed
80.
Travlos, G. S. (2006). Normal structure, function, and histology of the bone marrow. Toxicologic Pathology, 34(5), 548–565.PubMed
81.
Kelly, P. J. (1968). Anatomy, physiology, and pathology of the blood supply of bones. The Journal of Bone and Joint Surgery. American Volume, 50(4), 766–783.PubMed
82.
Augello, A., Kurth, T. B., & De Bari, C. (2010). Mesenchymal stem cells: a perspective from in vitro cultures to in vivo migration and niches. European Cells & Materials, 20, 121–133.
83.
84.
Kiel, M. J., & Morrison, S. J. (2008). Uncertainty in the niches that maintain haematopoietic stem cells. Nature Reviews. Immunology, 8(4), 290–301.PubMed
85.
Oh, I. H., & Kwon, K. R. (2010). Concise review: multiple niches for hematopoietic stem cell regulations. Stem Cells, 28(7), 1243–1249.PubMed
86.
Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., et al. (2004). Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nature Medicine, 10(8), 858–864.PubMed
87.
Hevehan, D. L., Papoutsakis, E. T., & Miller, W. M. (2000). Physiologically significant effects of pH and oxygen tension on granulopoiesis. Experimental Hematology, 28(3), 267–275.PubMed
88.
Doan, P. L., & Chute, J. P. (2012). The vascular niche: home for normal and malignant hematopoietic stem cells. Leukemia, 26(1), 54–62.PubMed
89.
Kaplan, R. N., Psaila, B., & Lyden, D. (2007). Niche-to-niche migration of bone-marrow-derived cells. Trends in Molecular Medicine, 13(2), 72–81.PubMed
90.
Lilly, A. J., Johnson, W. E., & Bunce, C. M. (2011). The haematopoietic stem cell niche: new insights into the mechanisms regulating haematopoietic stem cell behaviour. Stem Cells International, 2011, 274564.PubMedPubMedCentral
91.
Nagasawa, T., Omatsu, Y., & Sugiyama, T. (2011). Control of hematopoietic stem cells by the bone marrow stromal niche: the role of reticular cells. Trends in Immunology, 32(7), 315–320.PubMed
92.
Deutsch, V. R., & Tomer, A. (2013). Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside. British Journal of Haematology, 161(6), 778–793.PubMed
93.
Yu, M., & Cantor, A. B. (2012). Megakaryopoiesis and thrombopoiesis: an update on cytokines and lineage surface markers. Methods in Molecular Biology, 788, 291–303.PubMed
94.
Kanz, L., Lohr, G. W., & Fauser, A. A. (1987). Human megakaryocytic progenitor cells. Klinische Wochenschrift, 65(7), 297–307.PubMed
95.
Tijssen, M. R., & Ghevaert, C. (2013). Transcription factors in late megakaryopoiesis and related platelet disorders. Journal of Thrombosis and Haemostasis, 11(4), 593–604.PubMedPubMedCentral
96.
Kaur, G., Jalagadugula, G., Mao, G., & Rao, A. K. (2010). RUNX1/core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency. Blood, 115(15), 3128–3135.PubMedPubMedCentral
97.
Fowler, M., Borazanci, E., McGhee, L., Pylant, S. W., Williams, B. J., Glass, J., et al. (2006). RUNX1 (AML-1) and RUNX2 (AML-3) cooperate with prostate-derived Ets factor to activate transcription from the PSA upstream regulatory region. Journal of Cellular Biochemistry, 97(1), 1–17.PubMed
98.
Dakic, A., Metcalf, D., Di Rago, L., Mifsud, S., Wu, L., & Nutt, S. L. (2005). PU.1 regulates the commitment of adult hematopoietic progenitors and restricts granulopoiesis. The Journal of Experimental Medicine, 201(9), 1487–1502.PubMedPubMedCentral
99.
Nutt, S. L., Metcalf, D., D'Amico, A., Polli, M., & Wu, L. (2005). Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors. The Journal of Experimental Medicine, 201(2), 221–231.PubMedPubMedCentral
100.
Arinobu, Y., Mizuno, S., Chong, Y., Shigematsu, H., Iino, T., Iwasaki, H., et al. (2007). Reciprocal activation of GATA-1 and PU.1 marks initial specification of hematopoietic stem cells into myeloerythroid and myelolymphoid lineages. Cell Stem Cell, 1(4), 416–427.PubMed
101.
Chlon, T. M., Dore, L. C., & Crispino, J. D. (2012). Cofactor-mediated restriction of GATA-1 chromatin occupancy coordinates lineage-specific gene expression. Molecular Cell, 47(4), 608–621.PubMedPubMedCentral
102.
Dore, L. C., Chlon, T. M., Brown, C. D., White, K. P., & Crispino, J. D. (2012). Chromatin occupancy analysis reveals genome-wide GATA factor switching during hematopoiesis. Blood, 119(16), 3724–3733.PubMedPubMedCentral
103.
Malinge, S., Thiollier, C., Chlon, T. M., Dore, L. C., Diebold, L., Bluteau, O., et al. (2013). Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling. Blood, 121(13), 2440–2451.PubMedPubMedCentral
104.
Chagraoui, H., Kassouf, M., Banerjee, S., Goardon, N., Clark, K., Atzberger, A., et al. (2011). SCL-mediated regulation of the cell-cycle regulator p21 is critical for murine megakaryopoiesis. Blood, 118(3), 723–735.PubMed
105.
Lordier, L., Bluteau, D., Jalil, A., Legrand, C., Pan, J., Rameau, P., et al. (2012). RUNX1-induced silencing of non-muscle myosin heavy chain IIB contributes to megakaryocyte polyploidization. Nature Communications, 3, 717.PubMed
106.
Krumsiek, J., Marr, C., Schroeder, T., & Theis, F. J. (2011). Hierarchical differentiation of myeloid progenitors is encoded in the transcription factor network. PLoS One, 6(8), e22649.PubMedPubMedCentral
107.
Takayama, M., Fujita, R., Suzuki, M., Okuyama, R., Aiba, S., Motohashi, H., et al. (2010). Genetic analysis of hierarchical regulation for Gata1 and NF-E2 p45 gene expression in megakaryopoiesis. Molecular and Cellular Biology, 30(11), 2668–2680.PubMedPubMedCentral
108.
Vitrat, N., Letestu, R., Masse, A., Lazar, V., Vainchenker, W., & Debili, N. (2000). Thromboxane synthase has the same pattern of expression as platelet specific glycoproteins during human megakaryocyte differentiation. Thrombosis and Haemostasis, 83(5), 759–768.PubMed
109.
Bray, P. F., McKenzie, S. E., Edelstein, L. C., Nagalla, S., Delgrosso, K., Ertel, A., et al. (2013). The complex transcriptional landscape of the anucleate human platelet. BMC Genomics, 14, 1.PubMedPubMedCentral
110.
Edelstein, L. C., McKenzie, S. E., Shaw, C., Holinstat, M. A., Kunapuli, S. P., & Bray, P. F. (2013). MicroRNAs in platelet production and activation. Journal of Thrombosis and Haemostasis, 11(Suppl 1), 340–350.PubMed
111.
Guo, S., Lu, J., Schlanger, R., Zhang, H., Wang, J. Y., Fox, M. C., et al. (2010). MicroRNA miR-125a controls hematopoietic stem cell number. Proceedings of the National Academy of Sciences of the United States of America, 107(32), 14229–14234.PubMedPubMedCentral
112.
Lu, J., Guo, S., Ebert, B. L., Zhang, H., Peng, X., Bosco, J., et al. (2008). MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Developmental Cell, 14(6), 843–853.PubMedPubMedCentral
113.
Nagalla, S., Shaw, C., Kong, X., Kondkar, A. A., Edelstein, L. C., Ma, L., et al. (2011). Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood, 117(19), 5189–5197.PubMedPubMedCentral
114.
Carpinelli, M. R., Hilton, D. J., Metcalf, D., Antonchuk, J. L., Hyland, C. D., Mifsud, S. L., et al. (2004). Suppressor screen in Mpl−/− mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. Proceedings of the National Academy of Sciences of the United States of America, 101(17), 6553–6558.PubMedPubMedCentral
115.
de Graaf, C. A., Kauppi, M., Baldwin, T., Hyland, C. D., Metcalf, D., Willson, T. A., et al. (2010). Regulation of hematopoietic stem cells by their mature progeny. Proceedings of the National Academy of Sciences of the United States of America, 107(50), 21689–21694.PubMedPubMedCentral
116.
Metcalf, D., Carpinelli, M. R., Hyland, C., Mifsud, S., Dirago, L., Nicola, N. A., et al. (2005). Anomalous megakaryocytopoiesis in mice with mutations in the c-Myb gene. Blood, 105(9), 3480–3487.PubMed
117.
Kumar, M. S., Narla, A., Nonami, A., Mullally, A., Dimitrova, N., Ball, B., et al. (2011). Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood, 118(17), 4666–4673.PubMedPubMedCentral
118.
Hussein, K., Dralle, W., Theophile, K., Kreipe, H., & Bock, O. (2009). Megakaryocytic expression of miRNA 10a, 17-5p, 20a and 126 in Philadelphia chromosome-negative myeloproliferative neoplasm. Annals of Hematology, 88(4), 325–332.PubMed
119.
Lin, J., & Zhan, R. (2011). Advance of studies on role of miRNA in hematopoietic regulation and myeloproliferative neoplasms. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 19(4), 1071–1074.PubMed
120.
Edelstein, L. C., & Bray, P. F. (2012). Small RNAs as potential platelet therapeutics. Handbook of Experimental Pharmacology, 210, 435–445.PubMed
121.
Vigon, I., Mornon, J. P., Cocault, L., Mitjavila, M. T., Tambourin, P., Gisselbrecht, S., et al. (1992). Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proceedings of the National Academy of Sciences of the United States of America, 89(12), 5640–5644.PubMedPubMedCentral
122.
Bartley, T. D., Bogenberger, J., Hunt, P., Li, Y. S., Lu, H. S., Martin, F., et al. (1994). Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell, 77(7), 1117–1124.PubMed
123.
de Sauvage, F. J., Hass, P. E., Spencer, S. D., Malloy, B. E., Gurney, A. L., Spencer, S. A., et al. (1994). Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature, 369(6481), 533–538.PubMed
124.
Kaushansky, K. (1994). The mpl ligand: molecular and cellular biology of the critical regulator of megakaryocyte development. Stem Cells, 12(Suppl 1), 91–96. discussion 96-97.PubMed
125.
Sohma, Y., Akahori, H., Seki, N., Hori, T., Ogami, K., Kato, T., et al. (1994). Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Letters, 353(1), 57–61.PubMed
126.
Wendling, F., Maraskovsky, E., Debili, N., Florindo, C., Teepe, M., Titeux, M., et al. (1994). cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature, 369(6481), 571–574.PubMed
127.
Douglas, V. K., Tallman, M. S., Cripe, L. D., & Peterson, L. C. (2002). Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. American Journal of Clinical Pathology, 117(6), 844–850.PubMed
128.
Neumann, T. A., & Foote, M. (2000). Megakaryocyte growth and development factor (MGDF): an Mpl ligand and cytokine that regulates thrombopoiesis. Cytokines, Cellular & Molecular Therapy, 6(1), 47–56.
129.
Dong-Feng, Z., Ting, L., Yong, Z., Cheng, C., Xi, Z., & Pei-Yan, K. (2013). The TPO/c-MPL pathway in the bone marrow may protect leukemia cells from chemotherapy in AML patients. Pathology and Oncology Research. doi:10.​1007/​s12253-013-9696-z.PubMed
130.
Cosgrove, L. J., Sandrin, M. S., Rajasekariah, P., & McKenzie, I. F. (1986). A genomic clone encoding the alpha chain of the OKM1, LFA-1, and platelet glycoprotein IIb-IIIa molecules. Proceedings of the National Academy of Sciences of the United States of America, 83(3), 752–756.PubMedPubMedCentral
131.
Fitzgerald, L. A., Poncz, M., Steiner, B., Rall, S. C., Jr., Bennett, J. S., & Phillips, D. R. (1987). Comparison of cDNA-derived protein sequences of the human fibronectin and vitronectin receptor alpha-subunits and platelet glycoprotein IIb. Biochemistry, 26(25), 8158–8165.PubMed
132.
Kostyak, J. C., & Naik, U. P. (2007). Megakaryopoiesis: transcriptional insights into megakaryocyte maturation. Frontiers in Bioscience, 12, 2050–2062.PubMed
133.
Lanza, F., Kieffer, N., Phillips, D. R., & Fitzgerald, L. A. (1990). Characterization of the human platelet glycoprotein IIIa gene. Comparison with the fibronectin receptor beta-subunit gene. The Journal of Biological Chemistry, 265(30), 18098–18103.PubMed
134.
Levene, R. B., Williams, N. T., Lamaziere, J. M., & Rabellino, E. M. (1987). Human megakaryocytes. IV. Growth and characterization of clonable megakaryocyte progenitors in agar. Experimental Hematology, 15(2), 181–189.PubMed
135.
Majka, M., Ratajczak, J., Villaire, G., Kubiczek, K., Marquez, L. A., Janowska-Wieczorek, A., et al. (2002). Thrombopoietin, but not cytokines binding to gp130 protein-coupled receptors, activates MAPKp42/44, AKT, and STAT proteins in normal human CD34+ cells, megakaryocytes, and platelets. Experimental Hematology, 30(7), 751–760.PubMed
136.
Miyazaki, H. (1996). Physiologic role of TPO in thrombopoiesis. Stem Cells, 14(Suppl 1), 133–138.PubMed
137.
Monzen, S., Takahashi, K., Yoshino, H., Kasai-Eguchi, K., & Kashiwakura, I. (2011). Terminal maturation of megakaryocytes and platelet production by hematopoietic stem cells irradiated with heavy-ion beams. Radiation Research, 176(1), 8–16.PubMed
138.
Sumner, R., Crawford, A., Mucenski, M., & Frampton, J. (2000). Initiation of adult myelopoiesis can occur in the absence of c-Myb whereas subsequent development is strictly dependent on the transcription factor. Oncogene, 19(30), 3335–3342.PubMed
139.
Zimmet, J., & Ravid, K. (2000). Polyploidy: occurrence in nature, mechanisms, and significance for the megakaryocyte-platelet system. Experimental Hematology, 28(1), 3–16.PubMed
140.
Thon, J. N., & Italiano, J. E. (2012). Visualization and manipulation of the platelet and megakaryocyte cytoskeleton. Methods in Molecular Biology, 788, 109–125.PubMed
141.
Yamada, E. (1957). The fine structure of the megakaryocyte in the mouse spleen. Acta Anatomica (Basel), 29(3), 267–290.
142.
Behnke, O. (1968). An electron microscope study of the megacaryocyte of the rat bone marrow. I. The development of the demarcation membrane system and the platelet surface coat. Journal of Ultrastructure Research, 24(5), 412–433.PubMed
143.
Radley, J. M., & Haller, C. J. (1982). The demarcation membrane system of the megakaryocyte: a misnomer? Blood, 60(1), 213–219.PubMed
144.
Chen, Y., Aardema, J., Kale, S., Whichard, Z. L., Awomolo, A., Blanchard, E., et al. (2013). Loss of the F-BAR protein CIP4 reduces platelet production by impairing membrane-cytoskeleton remodeling. Blood, 122(10), 1695–706.PubMed
145.
Wang, W., Gilligan, D. M., Sun, S., Wu, X., & Reems, J. A. (2011). Distinct functional effects for dynamin 3 during megakaryocytopoiesis. Stem Cells and Development, 20(12), 2139–2151.PubMedPubMedCentral
146.
Patel-Hett, S., Wang, H., Begonja, A. J., Thon, J. N., Alden, E. C., Wandersee, N. J., et al. (2011). The spectrin-based membrane skeleton stabilizes mouse megakaryocyte membrane systems and is essential for proplatelet and platelet formation. Blood, 118(6), 1641–1652.PubMedPubMedCentral
147.
Van Nispen, T. O. T., Pannerden, H., De Haas, F., Geerts, W., Posthuma, G., Van Dijk, S., & Heijnen, H. F. (2010). The platelet interior revisited: electron tomography reveals tubular alpha-granule subtypes. Blood, 116(7), 1147–1156.
148.
Kamykowski, J., Carlton, P., Sehgal, S., & Storrie, B. (2011). Quantitative immunofluorescence mapping reveals little functional coclustering of proteins within platelet alpha-granules. Blood, 118(5), 1370–1373.PubMed
149.
Blair, P., & Flaumenhaft, R. (2009). Platelet alpha-granules: basic biology and clinical correlates. Blood Reviews, 23(4), 177–189.PubMedPubMedCentral
150.
Koseoglu, S., & Flaumenhaft, R. (2013). Advances in platelet granule biology. Current Opinion in Hematology, 20(5), 464–471.PubMed
151.
Albers, C. A., Cvejic, A., Favier, R., Bouwmans, E. E., Alessi, M. C., Bertone, P., et al. (2011). Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nature Genetics, 43(8), 735–737.PubMedPubMedCentral
152.
Gissen, P., Johnson, C. A., Morgan, N. V., Stapelbroek, J. M., Forshew, T., Cooper, W. N., et al. (2004). Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome. Nature Genetics, 36(4), 400–404.PubMed
153.
Gunay-Aygun, M., Falik-Zaccai, T. C., Vilboux, T., Zivony-Elboum, Y., Gumruk, F., Cetin, M., et al. (2011). NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet alpha-granules. Nature Genetics, 43(8), 732–734.PubMedPubMedCentral
154.
Kahr, W. H., Hinckley, J., Li, L., Schwertz, H., Christensen, H., Rowley, J. W., et al. (2011). Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nature Genetics, 43(8), 738–740.PubMed
155.
Urban, D., Li, L., Christensen, H., Pluthero, F. G., Chen, S. Z., Puhacz, M., et al. (2012). The VPS33B-binding protein VPS16B is required in megakaryocyte and platelet alpha-granule biogenesis. Blood, 120(25), 5032–5040.PubMedPubMedCentral
156.
Ambrosio, A. L., Boyle, J. A., & Di Pietro, S. M. (2012). Mechanism of platelet dense granule biogenesis: study of cargo transport and function of Rab32 and Rab38 in a model system. Blood, 120(19), 4072–4081.PubMedPubMedCentral
157.
Jedlitschky, G., Greinacher, A., & Kroemer, H. K. (2012). Transporters in human platelets: physiologic function and impact for pharmacotherapy. Blood, 119(15), 3394–3402.PubMed
158.
Niessen, J., Jedlitschky, G., Grube, M., Kawakami, H., Kamiie, J., Ohtsuki, S., et al. (2010). Expression of ABC-type transport proteins in human platelets. Pharmacogenetics and Genomics, 20(6), 396–400.PubMed
159.
Dhanjal, T. S., Pendaries, C., Ross, E. A., Larson, M. K., Protty, M. B., Buckley, C. D., et al. (2007). A novel role for PECAM-1 in megakaryocytokinesis and recovery of platelet counts in thrombocytopenic mice. Blood, 109(10), 4237–4244.PubMed
160.
Mazharian, A. (2012). Assessment of megakaryocyte migration and chemotaxis. Methods in Molecular Biology, 788, 275–288.PubMed
161.
Mazharian, A., Thomas, S. G., Dhanjal, T. S., Buckley, C. D., & Watson, S. P. (2010). Critical role of Src-Syk-PLC{gamma}2 signaling in megakaryocyte migration and thrombopoiesis. Blood, 116(5), 793–800.PubMed
162.
Reddi, A. H., Gay, R., Gay, S., & Miller, E. J. (1977). Transitions in collagen types during matrix-induced cartilage, bone, and bone marrow formation. Proceedings of the National Academy of Sciences of the United States of America, 74(12), 5589–5592.PubMedPubMedCentral
163.
Sabri, S., Jandrot-Perrus, M., Bertoglio, J., Farndale, R. W., Mas, V. M., Debili, N., et al. (2004). Differential regulation of actin stress fiber assembly and proplatelet formation by alpha2beta1 integrin and GPVI in human megakaryocytes. Blood, 104(10), 3117–3125.PubMed
164.
Zou, Z., Schmaier, A. A., Cheng, L., Mericko, P., Dickeson, S. K., Stricker, T. P., et al. (2009). Negative regulation of activated alpha-2 integrins during thrombopoiesis. Blood, 113(25), 6428–6439.PubMed
165.
Pallotta, I., Lovett, M., Rice, W., Kaplan, D. L., & Balduini, A. (2009). Bone marrow osteoblastic niche: a new model to study physiological regulation of megakaryopoiesis. PLoS One, 4(12), e8359.PubMedPubMedCentral
166.
Kopp, H. G., & Rafii, S. (2007). Thrombopoietic cells and the bone marrow vascular niche. Annals of the New York Academy of Sciences, 1106, 175–179.PubMed
167.
Schachtner, H., Calaminus, S. D., Sinclair, A., Monypenny, J., Blundell, M. P., Leon, C., et al. (2013). Megakaryocytes assemble podosomes that degrade matrix and protrude through basement membrane. Blood, 121(13), 2542–2552.PubMed
168.
Tavassoli, M., & Aoki, M. (1989). Localization of megakaryocytes in the bone marrow. Blood Cells, 15(1), 3–14.PubMed
169.
Corselli, M., Chin, C. J., Parekh, C., Sahaghian, A., Wang, W., Ge, S., et al. (2013). Perivascular support of human hematopoietic stem/progenitor cells. Blood, 121(15), 2891–2901.PubMedPubMedCentral
170.
Diaz-Flores, L., Jr., Gutierrez, R., Madrid, J. F., Acosta, E., Avila, J., Diaz-Flores, L., et al. (2012). Cell sources for cartilage repair; contribution of the mesenchymal perivascular niche. Frontiers in Bioscience (Scholar Edition), 4, 1275–1294.
171.
Diaz-Flores, L., Gutierrez, R., Madrid, J. F., Varela, H., Valladares, F., Acosta, E., et al. (2009). Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histology and Histopathology, 24(7), 909–969.PubMed
172.
Ding, L., Saunders, T. L., Enikolopov, G., & Morrison, S. J. (2012). Endothelial and perivascular cells maintain haematopoietic stem cells. Nature, 481(7382), 457–462.PubMedPubMedCentral
173.
Kunert, S., Meyer, I., Fleischhauer, S., Wannack, M., Fiedler, J., Shivdasani, R. A., et al. (2009). The microtubule modulator RanBP10 plays a critical role in regulation of platelet discoid shape and degranulation. Blood, 114(27), 5532–5540.PubMed
174.
Mazhuga, P. M., & Nosova, L. I. (1975). Proliferative characteristics of the endothelial cells and pericytes from the capillary vessels of rabbit bone marrow. Tsitologiia i Genetika, 9(5), 416–419.PubMed
175.
Wang, C. H., Wang, T. M., Young, T. H., Lai, Y. K., & Yen, M. L. (2013). The critical role of ECM proteins within the human MSC niche in endothelial differentiation. Biomaterials, 34(17), 4223–4234.PubMed
176.
Eto, K., Murphy, R., Kerrigan, S. W., Bertoni, A., Stuhlmann, H., Nakano, T., et al. (2002). Megakaryocytes derived from embryonic stem cells implicate CalDAG-GEFI in integrin signaling. Proceedings of the National Academy of Sciences of the United States of America, 99(20), 12819–12824.PubMedPubMedCentral
177.
Larson, M. K., & Watson, S. P. (2006). Regulation of proplatelet formation and platelet release by integrin alpha IIb beta3. Blood, 108(5), 1509–1514.PubMed
178.
Lu, X. G., Zhu, L., Wang, W. Q., Zhang, X. H., Zhao, X. Y., Xu, G. B., et al. (2005). Morphological study on the megakaryocytes with nuclear extrusion and nucleocytoplasmic separation in four cases. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 13(6), 1082–1085.PubMed
179.
Hartwig, J. H., & Italiano, J. E., Jr. (2006). Cytoskeletal mechanisms for platelet production. Blood Cells, Molecules & Diseases, 36(2), 99–103.
180.
Richardson, J. L., Shivdasani, R. A., Boers, C., Hartwig, J. H., & Italiano, J. E., Jr. (2005). Mechanisms of organelle transport and capture along proplatelets during platelet production. Blood, 106(13), 4066–4075.PubMedPubMedCentral
181.
Italiano, J. E., Jr., Patel-Hett, S., & Hartwig, J. H. (2007). Mechanics of proplatelet elaboration. Journal of Thrombosis and Haemostasis, 5(Suppl 1), 18–23.PubMed
182.
Schulze, H., Dose, M., Korpal, M., Meyer, I., Italiano, J. E., Jr., & Shivdasani, R. A. (2008). RanBP10 is a cytoplasmic guanine nucleotide exchange factor that modulates noncentrosomal microtubules. The Journal of Biological Chemistry, 283(20), 14109–14119.PubMedPubMedCentral
183.
Schwer, H. D., Lecine, P., Tiwari, S., Italiano, J. E., Jr., Hartwig, J. H., & Shivdasani, R. A. (2001). A lineage-restricted and divergent beta-tubulin isoform is essential for the biogenesis, structure and function of blood platelets. Current Biology, 11(8), 579–586.PubMed
184.
Junt, T., Schulze, H., Chen, Z., Massberg, S., Goerge, T., Krueger, A., et al. (2007). Dynamic visualization of thrombopoiesis within bone marrow. Science, 317(5845), 1767–1770.PubMed
185.
Italiano, J. E., Jr., Bergmeier, W., Tiwari, S., Falet, H., Hartwig, J. H., Hoffmeister, K. M., et al. (2003). Mechanisms and implications of platelet discoid shape. Blood, 101(12), 4789–4796.PubMed
186.
Zhang, L., Orban, M., Lorenz, M., Barocke, V., Braun, D., Urtz, N., et al. (2012). A novel role of sphingosine 1-phosphate receptor S1pr1 in mouse thrombopoiesis. The Journal of Experimental Medicine, 209(12), 2165–2181.PubMedPubMedCentral
187.
Mazo, I. B., & von Andrian, U. H. (1999). Adhesion and homing of blood-borne cells in bone marrow microvessels. Journal of Leukocyte Biology, 66(1), 25–32.PubMed
188.
Schmitt, A., Guichard, J., Masse, J. M., Debili, N., & Cramer, E. M. (2001). Of mice and men: comparison of the ultrastructure of megakaryocytes and platelets. Experimental Hematology, 29(11), 1295–1302.PubMed
189.
Di Michele, M., Van Geet, C., & Freson, K. (2012). Recent advances in platelet proteomics. Expert Review of Proteomics, 9(4), 451–466.PubMed
190.
Krishnan, S., Gaspari, M., Della Corte, A., Bianchi, P., Crescente, M., Cerletti, C., et al. (2011). OFFgel-based multidimensional LC-MS/MS approach to the cataloguing of the human platelet proteome for an interactomic profile. Electrophoresis, 32(6–7), 686–695.PubMed
191.
Premsler, T., Lewandrowski, U., Sickmann, A., & Zahedi, R. P. (2011). Phosphoproteome analysis of the platelet plasma membrane. Methods in Molecular Biology, 728, 279–290.PubMed
192.
Qureshi, A. H., Chaoji, V., Maiguel, D., Faridi, M. H., Barth, C. J., Salem, S. M., et al. (2009). Proteomic and phospho-proteomic profile of human platelets in basal, resting state: insights into integrin signaling. PLoS One, 4(10), e7627.PubMedPubMedCentral
193.
Senis, Y., & Garcia, A. (2012). Platelet proteomics: state of the art and future perspective. Methods in Molecular Biology, 788, 367–399.PubMed
194.
Zufferey, A., Fontana, P., Reny, J. L., Nolli, S., & Sanchez, J. C. (2012). Platelet proteomics. Mass Spectrometry Reviews, 31(2), 331–351.PubMed
195.
Di Michele, M., Van Geet, C., & Freson, K. (2012). Proteomics to unravel platelet-related diseases and identify novel anti-platelet drugs. Current Medicinal Chemistry, 19(27), 4662–4670.PubMed
196.
Parguina, A. F., Rosa, I., & Garcia, A. (2012). Proteomics applied to the study of platelet-related diseases: aiding the discovery of novel platelet biomarkers and drug targets. Journal of Proteomics, 76, 275–286.PubMed
197.
Aatonen, M., Gronholm, M., & Siljander, P. R. (2012). Platelet-derived microvesicles: multitalented participants in intercellular communication. Seminars in Thrombosis and Hemostasis, 38(1), 102–113.PubMed
198.
Hess, M. W., & Siljander, P. (2001). Procoagulant platelet balloons: evidence from cryopreparation and electron microscopy. Histochemistry and Cell Biology, 115(5), 439–443.PubMed
199.
Siljander, P. R. (2011). Platelet-derived microparticles—an updated perspective. Thrombosis Research, 127(Suppl 2), S30–33.PubMed
200.
Shai, E., Rosa, I., Parguina, A. F., Motahedeh, S., Varon, D., & Garcia, A. (2012). Comparative analysis of platelet-derived microparticles reveals differences in their amount and proteome depending on the platelet stimulus. Journal of Proteomics, 76, 287–296.PubMed
201.
Dowal, L., Yang, W., Freeman, M. R., Steen, H., & Flaumenhaft, R. (2011). Proteomic analysis of palmitoylated platelet proteins. Blood, 118(13), e62–73.PubMedPubMedCentral
202.
Schulz, C., Leuschen, N. V., Frohlich, T., Lorenz, M., Pfeiler, S., Gleissner, C. A., et al. (2010). Identification of novel downstream targets of platelet glycoprotein VI activation by differential proteome analysis: implications for thrombus formation. Blood, 115(20), 4102–4110.PubMed
203.
Wright, B., Stanley, R. G., Kaiser, W. J., Mills, D. J., & Gibbins, J. M. (2011). Analysis of protein networks in resting and collagen receptor (GPVI)-stimulated platelet sub-proteomes. Proteomics, 11(23), 4588–4592.PubMed
204.
Hamberg, M., & Samuelsson, B. (1974). Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proceedings of the National Academy of Sciences of the United States of America, 71(9), 3400–3404.PubMedPubMedCentral
205.
Clarke, R. J., Mayo, G., Price, P., & FitzGerald, G. A. (1991). Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. The New England Journal of Medicine, 325(16), 1137–1141.PubMed
206.
Samuelsson, B., Goldyne, M., Granstrom, E., Hamberg, M., Hammarstrom, S., & Malmsten, C. (1978). Prostaglandins and thromboxanes. Annual Review of Biochemistry, 47, 997–1029.PubMed
207.
Steinert, B. W., Tang, D. G., Grossi, I. M., Umbarger, L. A., & Honn, K. V. (1993). Studies on the role of platelet eicosanoid metabolism and integrin alpha IIb beta 3 in tumor-cell-induced platelet aggregation. International Journal of Cancer, 54(1), 92–101.
208.
Maskrey, B. H., Bermudez-Fajardo, A., Morgan, A. H., Stewart-Jones, E., Dioszeghy, V., Taylor, G. W., et al. (2007). Activated platelets and monocytes generate four hydroxyphosphatidylethanolamines via lipoxygenase. The Journal of Biological Chemistry, 282(28), 20151–20163.PubMed
209.
Morgan, L. T., Thomas, C. P., Kuhn, H., & O'Donnell, V. B. (2010). Thrombin-activated human platelets acutely generate oxidized docosahexaenoic-acid-containing phospholipids via 12-lipoxygenase. The Biochemical Journal, 431(1), 141–148.PubMed
210.
Chen, Y. Q., & Honn, K. V. (1993). Eicosanoid regulation of tumor cell-platelet and -endothelium interaction during arrest and extravasation. In: S. Nigam, K. Honn, L. Marnett, & T. Walden, Jr. (Eds.). Eicosanoids and other bioactive lipids in cancer, inflammation and radiation injury. Developments in oncology, vol. 71, pp. 613–617. Springer: New York.
211.
Honn, K. V., Tang, D. G., Grossi, I., Duniec, Z. M., Timar, J., Renaud, C., et al. (1994). Tumor cell-derived 12(S)-hydroxyeicosatetraenoic acid induces microvascular endothelial cell retraction. Cancer Research, 54(2), 565–574.PubMed
212.
Ruebsaamen, K., Liebisch, G., Boettcher, A., & Schmitz, G. (2010). Lipidomic analysis of platelet senescence. Transfusion, 50(8), 1665–1676.PubMed
213.
Clark, S. R., Thomas, C. P., Hammond, V. J., Aldrovandi, M., Wilkinson, G. W., Hart, K. W., et al. (2013). Characterization of platelet aminophospholipid externalization reveals fatty acids as molecular determinants that regulate coagulation. Proceedings of the National Academy of Sciences of the United States of America, 110(15), 5875–5880.PubMedPubMedCentral
214.
Dolegowska, B., Lubkowska, A., & De Girolamo, L. (2012). Platelet lipidomic. Journal of Biological Regulators and Homeostatic Agents, 26(2 Suppl 1), 23S–33S.PubMed
215.
Hammad, S. M. (2011). Blood sphingolipids in homeostasis and pathobiology. Advances in Experimental Medicine and Biology, 721, 57–66.PubMed
216.
Tam, V. C. (2013). Lipidomic profiling of bioactive lipids by mass spectrometry during microbial infections. Seminars in Immunology, 25(3), 240–248.PubMed
217.
Albanese, A., Licata, M. E., Polizzi, B., & Campisi, G. (2013). Platelet-rich plasma (PRP) in dental and oral surgery: from the wound healing to bone regeneration. Immunity & Ageing, 10(1), 23.
218.
Galliera, E., Corsi, M. M., & Banfi, G. (2012). Platelet rich plasma therapy: inflammatory molecules involved in tissue healing. Journal of Biological Regulators and Homeostatic Agents, 26(2 Suppl 1), 35S–42S.PubMed
219.
Lubkowska, A., Dolegowska, B., & Banfi, G. (2012). Growth factor content in PRP and their applicability in medicine. Journal of Biological Regulators and Homeostatic Agents, 26(2 Suppl 1), 3S–22S.PubMed
220.
Stanco, D., Vigano, M., Croiset, S. J., & De Girolamo, L. (2012). Applications and limits of platelet-rich plasma in sports related injuries. Journal of Biological Regulators and Homeostatic Agents, 26(2 Suppl 1), 53S–61S.PubMed
221.
Cimmino, G., & Golino, P. (2013). Platelet biology and receptor pathways. Journal of Cardiovascular Translational Research, 6(3), 299–309.PubMed
222.
Italiano, J. E., Jr. (2013). Unraveling mechanisms that control platelet production. Seminars in Thrombosis and Hemostasis, 39(1), 15–24.PubMed
223.
Kenney, D. M., & Linck, R. W. (1985). The cystoskeleton of unstimulated blood platelets: structure and composition of the isolated marginal microtubular band. Journal of Cell Science, 78, 1–22.PubMed
224.
Kowit, J. D., Linck, R. W., & Kenney, D. M. (1988). Isolated cytoskeletons of human blood platelets: dark-field imaging of coiled and uncoiled microtubules. Biology of the Cell, 64(3), 283–291.PubMed
225.
Patel-Hett, S., Richardson, J. L., Schulze, H., Drabek, K., Isaac, N. A., Hoffmeister, K., et al. (2008). Visualization of microtubule growth in living platelets reveals a dynamic marginal band with multiple microtubules. Blood, 111(9), 4605–4616.PubMedPubMedCentral
226.
Radley, J. M., & Hartshorn, M. A. (1987). Megakaryocyte fragments and the microtubule coil. Blood Cells, 12(3), 603–614.PubMed
227.
Hartwig, J. H. (2006). The platelet: form and function. Seminars in Hematology, 43(1 Suppl 1), S94–100.PubMed
228.
Hartwig, J. H., Barkalow, K., Azim, A., & Italiano, J. (1999). The elegant platelet: signals controlling actin assembly. Thrombosis and Haemostasis, 82(2), 392–398.PubMed
229.
Boyles, J., Fox, J. E., Phillips, D. R., & Stenberg, P. E. (1985). Organization of the cytoskeleton in resting, discoid platelets: preservation of actin filaments by a modified fixation that prevents osmium damage. The Journal of Cell Biology, 101(4), 1463–1472.PubMed
230.
White, J. G. (1972). Interaction of membrane systems in blood platelets. The American Journal of Pathology, 66(2), 295–312.PubMedPubMedCentral
231.
Escolar, G., Leistikow, E., & White, J. G. (1989). The fate of the open canalicular system in surface and suspension-activated platelets. Blood, 74(6), 1983–1988.PubMed
232.
Barkalow, K. L., Italiano, J. E., Jr., Chou, D. E., Matsuoka, Y., Bennett, V., & Hartwig, J. H. (2003). Alpha-adducin dissociates from F-actin and spectrin during platelet activation. The Journal of Cell Biology, 161(3), 557–570.PubMedPubMedCentral
233.
Hartwig, J. H., & DeSisto, M. (1991). The cytoskeleton of the resting human blood platelet: structure of the membrane skeleton and its attachment to actin filaments. The Journal of Cell Biology, 112(3), 407–425.PubMed
234.
Cranmer, S. L., Pikovski, I., Mangin, P., Thompson, P. E., Domagala, T., Frazzetto, M., et al. (2005). Identification of a unique filamin A binding region within the cytoplasmic domain of glycoprotein Ibalpha. The Biochemical Journal, 387(Pt 3), 849–858.PubMedPubMedCentral
235.
Dai, K., Bodnar, R., Berndt, M. C., & Du, X. (2005). A critical role for 14-3-3zeta protein in regulating the VWF binding function of platelet glycoprotein Ib-IX and its therapeutic implications. Blood, 106(6), 1975–1981.PubMedPubMedCentral
236.
Gitz, E., Koopman, C. D., Giannas, A., Koekman, C. A., van den Heuvel, D. J., Deckmyn, H., et al. (2013). Platelet interaction with von Willebrand factor is enhanced by shear-induced clustering of glycoprotein Ibalpha. Haematologica, 98(11), 1810–1818.PubMedPubMedCentral
237.
Li, S., Wang, Z., Liao, Y., Zhang, W., Shi, Q., Yan, R., et al. (2010). The glycoprotein Ibalpha-von Willebrand factor interaction induces platelet apoptosis. Journal of Thrombosis and Haemostasis, 8(2), 341–350.PubMed
238.
Mangin, P., David, T., Lavaud, V., Cranmer, S. L., Pikovski, I., Jackson, S. P., et al. (2004). Identification of a novel 14-3-3zeta binding site within the cytoplasmic tail of platelet glycoprotein Ibalpha. Blood, 104(2), 420–427.PubMed
239.
Mu, F. T., Andrews, R. K., Arthur, J. F., Munday, A. D., Cranmer, S. L., Jackson, S. P., et al. (2008). A functional 14-3-3zeta-independent association of PI3-kinase with glycoprotein Ib alpha, the major ligand-binding subunit of the platelet glycoprotein Ib-IX-V complex. Blood, 111(9), 4580–4587.PubMedPubMedCentral
240.
Zwaal, R. F., & Schroit, A. J. (1997). Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood, 89(4), 1121–1132.PubMed
241.
Furusawa, M., Tsuchiy, H., Nagayama, M., Tanaka, T., Nakaya, K. I., & Iinumac, M. (2003). Anti-platelet and membrane-rigidifying flavonoids in brownish scale of onions. Journal of Health Science, 49(6), 475–480.
242.
Winocour, P. D., Bryszewska, M., Watala, C., Rand, M. L., Epand, R. M., Kinlough-Rathbone, R. L., et al. (1990). Reduced membrane fluidity in platelets from diabetic patients. Diabetes, 39(2), 241–244.PubMed
243.
Gerrits, A. J., Gitz, E., Koekman, C. A., Visseren, F. L., van Haeften, T. W., & Akkerman, J. W. (2012). Induction of insulin resistance by the adipokines resistin, leptin, plasminogen activator inhibitor-1 and retinol binding protein 4 in human megakaryocytes. Haematologica, 97(8), 1149–1157.PubMedPubMedCentral
244.
De Caterina, R., Marchetti, P., Bernini, W., Giannarelli, R., Giannessi, D., & Navalesi, R. (1989). The direct effects of metformin on platelet function in vitro. European Journal of Clinical Pharmacology, 37(2), 211–213.PubMed
245.
Gin, H., Freyburger, G., Boisseau, M., & Aubertin, J. (1989). Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics. Diabetes Research and Clinical Practice, 6(1), 61–67.PubMed
246.
Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002). Metformin: an update. Annals of Internal Medicine, 137(1), 25–33.PubMed
247.
Wiwanitkit, V. (2011). Metformin high dosage and bleeding episode: a clinical case study. Indian Journal of Endocrinology and Metabolism, 15(2), 132–133.PubMedPubMedCentral
248.
Protti, A., Lecchi, A., Fortunato, F., Artoni, A., Greppi, N., Vecchio, S., et al. (2012). Metformin overdose causes platelet mitochondrial dysfunction in humans. Critical Care, 16(5), R180.PubMedPubMedCentral
249.
Harper, M. T., & Poole, A. W. (2013). Chloride channels are necessary for full platelet phosphatidylserine exposure and procoagulant activity. Cell Death and Disease, 4, e969.PubMedPubMedCentral
250.
Gilligan, D. M., Sarid, R., & Weese, J. (2002). Adducin in platelets: activation-induced phosphorylation by PKC and proteolysis by calpain. Blood, 99(7), 2418–2426.PubMed
251.
Tamaru, S., Fukuta, T., Kaibuchi, K., Matsuoka, Y., Shiku, H., & Nishikawa, M. (2005). Rho-kinase induces association of adducin with the cytoskeleton in platelet activation. Biochemical and Biophysical Research Communications, 332(2), 347–351.PubMed
252.
Lind, S. E., Yin, H. L., & Stossel, T. P. (1982). Human platelets contain gelsolin. A regulator of actin filament length. Journal of Clinical Investigation, 69(6), 1384–1387.PubMedPubMedCentral
253.
Wang, L. L., & Bryan, J. (1981). Isolation of calcium-dependent platelet proteins that interact with actin. Cell, 25(3), 637–649.PubMed
254.
Bennett, J. S., Zigmond, S., Vilaire, G., Cunningham, M. E., & Bednar, B. (1999). The platelet cytoskeleton regulates the affinity of the integrin alpha(IIb)beta(3) for fibrinogen. The Journal of Biological Chemistry, 274(36), 25301–25307.PubMed
255.
Davidson, M. M., & Haslam, R. J. (1994). Dephosphorylation of cofilin in stimulated platelets: roles for a GTP-binding protein and Ca2+. The Biochemical Journal, 301(Pt 1), 41–47.PubMedPubMedCentral
256.
Machesky, L. M., Reeves, E., Wientjes, F., Mattheyse, F. J., Grogan, A., Totty, N. F., et al. (1997). Mammalian actin-related protein 2/3 complex localizes to regions of lamellipodial protrusion and is composed of evolutionarily conserved proteins. The Biochemical Journal, 328(Pt 1), 105–112.PubMedPubMedCentral
257.
Mahoney, N. M., Janmey, P. A., & Almo, S. C. (1997). Structure of the profilin-poly-l-proline complex involved in morphogenesis and cytoskeletal regulation. Nature Structural Biology, 4(11), 953–960.PubMed
258.
Barkalow, K., Witke, W., Kwiatkowski, D. J., & Hartwig, J. H. (1996). Coordinated regulation of platelet actin filament barbed ends by gelsolin and capping protein. The Journal of Cell Biology, 134(2), 389–399.PubMed
259.
Nachmias, V. T., Golla, R., Casella, J. F., & Barron-Casella, E. (1996). Cap Z, a calcium insensitive capping protein in resting and activated platelets. FEBS Letters, 378(3), 258–262.PubMed
260.
White, J. G. (1972). Exocytosis of secretory organelles from blood platelets incubated with cationic polypeptides. The American Journal of Pathology, 69(1), 41–54.PubMedPubMedCentral
261.
White, J. G., & Estensen, R. D. (1972). Degranulation of discoid platelets. The American Journal of Pathology, 68(2), 289–302.PubMedPubMedCentral
262.
Chen, D., Bernstein, A. M., Lemons, P. P., & Whiteheart, S. W. (2000). Molecular mechanisms of platelet exocytosis: role of SNAP-23 and syntaxin 2 in dense core granule release. Blood, 95(3), 921–929.PubMed
263.
Marks, M. S. (2012). SNARing platelet granule secretion. Blood, 120(12), 2355–2357.PubMed
264.
Peters, C. G., Michelson, A. D., & Flaumenhaft, R. (2012). Granule exocytosis is required for platelet spreading: differential sorting of alpha-granules expressing VAMP-7. Blood, 120(1), 199–206.PubMedPubMedCentral
265.
Fukuda, M., & Kanno, E. (2005). Analysis of the role of Rab27 effector Slp4-a/Granuphilin-a in dense-core vesicle exocytosis. Methods in Enzymology, 403, 445–457.PubMed
266.
Shirakawa, R., Higashi, T., Tabuchi, A., Yoshioka, A., Nishioka, H., Fukuda, M., et al. (2004). Munc13-4 is a GTP-Rab27-binding protein regulating dense core granule secretion in platelets. The Journal of Biological Chemistry, 279(11), 10730–10737.PubMed
267.
Al Hawas, R., Ren, Q., Ye, S., Karim, Z. A., Filipovich, A. H., & Whiteheart, S. W. (2012). Munc18b/STXBP2 is required for platelet secretion. Blood, 120(12), 2493–2500.PubMedPubMedCentral
268.
Ye, S., Karim, Z. A., Al Hawas, R., Pessin, J. E., Filipovich, A. H., & Whiteheart, S. W. (2012). Syntaxin-11, but not syntaxin-2 or syntaxin-4, is required for platelet secretion. Blood, 120(12), 2484–2492.PubMedPubMedCentral
269.
Santos-Martinez, M. J., Medina, C., Jurasz, P., & Radomski, M. W. (2008). Role of metalloproteinases in platelet function. Thrombosis Research, 121(4), 535–542.PubMed
270.
Gleissner, C. A., von Hundelshausen, P., & Ley, K. (2008). Platelet chemokines in vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(11), 1920–1927.PubMedPubMedCentral
271.
Brandt, E., Petersen, F., Ludwig, A., Ehlert, J. E., Bock, L., & Flad, H. D. (2000). The beta-thromboglobulins and platelet factor 4: blood platelet-derived CXC chemokines with divergent roles in early neutrophil regulation. Journal of Leukocyte Biology, 67(4), 471–478.PubMed
272.
Mellembakken, J. R., Solum, N. O., Ueland, T., Videm, V., & Aukrust, P. (2001). Increased concentrations of soluble CD40 ligand, RANTES and GRO-alpha in preeclampsia—possible role of platelet activation. Thrombosis and Haemostasis, 86(5), 1272–1276.PubMed
273.
Fukami, M. H., & Salganicoff, L. (1977). Human platelet storage organelles. A review. Thrombosis and Haemostasis, 38(4), 963–970.PubMed
274.
Emiliani, C., Martino, S., Orlacchio, A., Vezza, R., Nenci, G. G., & Gresele, P. (1995). Platelet glycohydrolase activities: characterization and release. Cell Biochemistry and Function, 13(1), 31–39.PubMed
275.
Gordon, J. L. (1975). Blood platelet lysosomes and their contribution to the pathophysiological role of platelets. Frontiers of Biology, 43(4), 3–31.PubMed
276.
Metzelaar, M. J., & Clevers, H. C. (1992). Lysosomal membrane glycoproteins in platelets. Thrombosis and Haemostasis, 68(4), 378–382.PubMed
277.
Waite, M., & Griffin, H. D. (1976). The phospholipases A of lysosomes. Frontiers of Biology, 45, 257–305.PubMed
278.
Dangel, O., Mergia, E., Karlisch, K., Groneberg, D., Koesling, D., & Friebe, A. (2010). Nitric oxide-sensitive guanylyl cyclase is the only nitric oxide receptor mediating platelet inhibition. Journal of Thrombosis and Haemostasis, 8(6), 1343–1352.PubMed
279.
Sabetkar, M., Naseem, K. M., Tullett, J. M., Friebe, A., Koesling, D., & Bruckdorfer, K. R. (2001). Synergism between nitric oxide and hydrogen peroxide in the inhibition of platelet function: the roles of soluble guanylyl cyclase and vasodilator-stimulated phosphoprotein. Nitric Oxide, 5(3), 233–242.PubMed
280.
Wilson, L. S., Elbatarny, H. S., Crawley, S. W., Bennett, B. M., & Maurice, D. H. (2008). Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions. Proceedings of the National Academy of Sciences of the United States of America, 105(36), 13650–13655.PubMedPubMedCentral
281.
Audet, M., & Bouvier, M. (2012). Restructuring G-protein-coupled receptor activation. Cell, 151(1), 14–23.PubMed
282.
Katritch, V., Cherezov, V., & Stevens, R. C. (2013). Structure-function of the G protein-coupled receptor superfamily. Annual Review of Pharmacology and Toxicology, 53, 531–556.PubMedPubMedCentral
283.
Venkatakrishnan, A. J., Deupi, X., Lebon, G., Tate, C. G., Schertler, G. F., & Babu, M. M. (2013). Molecular signatures of G-protein-coupled receptors. Nature, 494(7436), 185–194.PubMed
284.
Stalker, T. J., Newman, D. K., Ma, P., Wannemacher, K. M., & Brass, L. F. (2012). Platelet signaling. Handbook of Experimental Pharmacology, 210, 59–85.PubMed
285.
Zucker, M. B., & Nachmias, V. T. (1985). Platelet activation. Arteriosclerosis, 5(1), 2–18.PubMed
286.
Moers, A., Nieswandt, B., Massberg, S., Wettschureck, N., Gruner, S., Konrad, I., et al. (2003). G13 is an essential mediator of platelet activation in hemostasis and thrombosis. Nature Medicine, 9(11), 1418–1422.PubMed
287.
Noe, L., Peeters, K., Izzi, B., Van Geet, C., & Freson, K. (2010). Regulators of platelet cAMP levels: clinical and therapeutic implications. Current Medicinal Chemistry, 17(26), 2897–2905.PubMed
288.
Smolenski, A. (2012). Novel roles of cAMP/cGMP-dependent signaling in platelets. Journal of Thrombosis and Haemostasis, 10(2), 167–176.PubMed
289.
Rolfe, B. E., Worth, N. F., World, C. J., Campbell, J. H., & Campbell, G. R. (2005). Rho and vascular disease. Atherosclerosis, 183(1), 1–16.PubMed
290.
Aslan, J. E., & McCarty, O. J. (2013). Rho GTPases in platelet function. Journal of Thrombosis and Haemostasis, 11(1), 35–46.PubMedPubMedCentral
291.
292.
Goggs, R., & Poole, A. W. (2012). Platelet signaling—a primer. Journal of Veterinary Emergency and Critical Care (San Antonio, Tex.), 22(1), 5–29.
293.
Kauskot, A., & Hoylaerts, M. F. (2012). Platelet receptors. Handbook of Experimental Pharmacology, 210, 23–57.PubMed
294.
Pai, V. P., Marshall, A. M., Hernandez, L. L., Buckley, A. R., & Horseman, N. D. (2009). Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival. Breast Cancer Research, 11(6), R81.PubMedPubMedCentral
295.
Kundumani-Sridharan, V., Dyukova, E., Hansen, D. E., 3rd, & Rao, G. N. (2013). 12/15-Lipoxygenase mediates high-fat diet-induced endothelial tight junction disruption and monocyte transmigration: a new role for 15(S)-hydroxyeicosatetraenoic acid in endothelial cell dysfunction. The Journal of Biological Chemistry, 288(22), 15830–15842.PubMed
296.
Garcia, M. C., & Kim, H. Y. (1997). Mobilization of arachidonate and docosahexaenoate by stimulation of the 5-HT2A receptor in rat C6 glioma cells. Brain Research, 768(1–2), 43–48.PubMed
297.
Kurrasch-Orbaugh, D. M., Parrish, J. C., Watts, V. J., & Nichols, D. E. (2003). A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases. Journal of Neurochemistry, 86(4), 980–991.PubMed
298.
Pakala, R. (2004). Serotonin and thromboxane A2 stimulate platelet-derived microparticle-induced smooth muscle cell proliferation. Cardiovascular Radiation Medicine, 5(1), 20–26.PubMed
299.
Dutta-Roy, A. K., & Sinha, A. K. (1987). Purification and properties of prostaglandin E1/prostacyclin receptor of human blood platelets. The Journal of Biological Chemistry, 262(26), 12685–12691.PubMed
300.
Weksler, B. B., Marcus, A. J., & Jaffe, E. A. (1977). Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 74(9), 3922–3926.PubMedPubMedCentral
301.
Bunting, S., Gryglewski, R., Moncada, S., & Vane, J. R. (1976). Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins, 12(6), 897–913.PubMed
302.
Moncada, S., Gryglewski, R., Bunting, S., & Vane, J. R. (1976). An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature, 263(5579), 663–665.PubMed
303.
Boyanova, D., Nilla, S., Birschmann, I., Dandekar, T., & Dittrich, M. (2012). PlateletWeb: a systems biologic analysis of signaling networks in human platelets. Blood, 119(3), e22–34.PubMed
304.
Dittrich, M., Birschmann, I., Mietner, S., Sickmann, A., Walter, U., & Dandekar, T. (2008). Platelet protein interactions: map, signaling components, and phosphorylation groundstate. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(7), 1326–1331.PubMed
305.
Lyons, R. M., Stanford, N., & Majerus, P. W. (1975). Thrombin-induced protein phosphorylation in human platelets. The Journal of Clinical Investigation, 56(4), 924–936.PubMedPubMedCentral
306.
Yamanaka, M., Kume, S., Kariya, T., & Tanabe, A. (1979). cAMP-dependent protein kinase in human platelets and effect of prostaglandin E1 on its endogenous substrates (author’s transl). Nihon Ketsueki Gakkai Zasshi, 42(3), 541–542.PubMed
307.
de Rooij, J., Zwartkruis, F. J., Verheijen, M. H., Cool, R. H., Nijman, S. M., Wittinghofer, A., et al. (1998). Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature, 396(6710), 474–477.PubMed
308.
Sand, C., Grandoch, M., Borgermann, C., Oude Weernink, P. A., Mahlke, Y., Schwindenhammer, B., et al. (2010). 8-pCPT-conjugated cyclic AMP analogs exert thromboxane receptor antagonistic properties. Thrombosis and Haemostasis, 103(3), 662–678.PubMed
309.
Siess, W., Winegar, D. A., & Lapetina, E. G. (1990). Rap1-B is phosphorylated by protein kinase A in intact human platelets. Biochemical and Biophysical Research Communications, 170(2), 944–950.PubMed
310.
Mellion, B. T., Ignarro, L. J., Ohlstein, E. H., Pontecorvo, E. G., Hyman, A. L., & Kadowitz, P. J. (1981). Evidence for the inhibitory role of guanosine 3′,5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood, 57(5), 946–955.PubMed
311.
Marquis, N. R., Vigdahl, R. L., & Tavormina, P. A. (1969). Platelet aggregation. I. Regulation by cyclic AMP and prostaglandin E1. Biochemical and Biophysical Research Communications, 36(6), 965–972.PubMed
312.
Salzman, E. W., & Neri, L. L. (1969). Cyclic 3′,5′-adenosine monophosphate in human blood platelets. Nature, 224(5219), 609–610.PubMed
313.
Salzman, E. W. (1967). ADP-platelet aggregation. Thrombosis et Diathesis Haemorrhagica. Supplementum, 26, 197–199.PubMed
314.
Brodie, G. N., Baenziger, N. L., Chase, L. R., & Majerus, P. W. (1972). The effects of thrombin on adenyl cyclase activity and a membrane protein from human platelets. The Journal of Clinical Investigation, 51(1), 81–88.PubMedPubMedCentral
315.
Hamberg, M., Svensson, J., Wakabayashi, T., & Samuelsson, B. (1974). Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proceedings of the National Academy of Sciences of the United States of America, 71(2), 345–349.PubMedPubMedCentral
316.
Hamberg, M., Svensson, J., & Samuelsson, B. (1975). Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proceedings of the National Academy of Sciences of the United States of America, 72(8), 2994–2998.PubMedPubMedCentral
317.
Young, A., Chapman, O., Connor, C., Poole, C., Rose, P., & Kakkar, A. K. (2012). Thrombosis and cancer. Nature Reviews. Clinical Oncology, 9(8), 437–449.PubMed
318.
Langer, F., & Bokemeyer, C. (2012). Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor. Hamostaseologie, 32(2), 95–104.PubMed
319.
van den Berg, Y. W., Osanto, S., Reitsma, P. H., & Versteeg, H. H. (2012). The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood, 119(4), 924–932.PubMed
320.
Stefanini, L., Boulaftali, Y., Ouellette, T. D., Holinstat, M., Desire, L., Leblond, B., et al. (2012). Rap1-Rac1 circuits potentiate platelet activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 32(2), 434–441.PubMedPubMedCentral
321.
Tao, L., Zhang, Y., Xi, X., & Kieffer, N. (2010). Recent advances in the understanding of the molecular mechanisms regulating platelet integrin alphaIIbbeta3 activation. Protein & Cell, 1(7), 627–637.
322.
Watanabe, N. (2010). RIAM: bridge between Rap1 and integrin. Rinshō Ketsueki, 51(6), 377–383.PubMed
323.
Wynne, J. P., Wu, J., Su, W., Mor, A., Patsoukis, N., Boussiotis, V. A., et al. (2012). Rap1-interacting adapter molecule (RIAM) associates with the plasma membrane via a proximity detector. The Journal of Cell Biology, 199(2), 317–330.PubMedPubMedCentral
324.
Stefanini, L., & Bergmeier, W. (2010). CalDAG-GEFI and platelet activation. Platelets, 21(4), 239–243.PubMed
325.
Subramanian, H., Zahedi, R. P., Sickmann, A., Walter, U., & Gambaryan, S. (2013). Phosphorylation of CalDAG-GEFI by protein kinase A prevents Rap1b activation. Journal of Thrombosis and Haemostasis, 11(8), 1574–1582.PubMed
326.
Ridley, A. J. (2011). Life at the leading edge. Cell, 145(7), 1012–1022.PubMed
327.
Ridley, A. J., & Hall, A. (1992). The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell, 70(3), 389–399.PubMed
328.
Ridley, A. J., Paterson, H. F., Johnston, C. L., Diekmann, D., & Hall, A. (1992). The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell, 70(3), 401–410.PubMed
329.
Klages, B., Brandt, U., Simon, M. I., Schultz, G., & Offermanns, S. (1999). Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. The Journal of Cell Biology, 144(4), 745–754.PubMedPubMedCentral
330.
Pleines, I., Hagedorn, I., Gupta, S., May, F., Chakarova, L., van Hengel, J., et al. (2012). Megakaryocyte-specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis. Blood, 119(4), 1054–1063.PubMed
331.
Schoenwaelder, S. M., Hughan, S. C., Boniface, K., Fernando, S., Holdsworth, M., Thompson, P. E., et al. (2002). RhoA sustains integrin alpha IIbbeta 3 adhesion contacts under high shear. The Journal of Biological Chemistry, 277(17), 14738–14746.PubMed
332.
Fujita, A., Saito, Y., Ishizaki, T., Maekawa, M., Fujisawa, K., Ushikubi, F., et al. (1997). Integrin-dependent translocation of p160ROCK to cytoskeletal complex in thrombin-stimulated human platelets. The Biochemical Journal, 328(Pt 3), 769–775.PubMedPubMedCentral
333.
Huang, J. S., Dong, L., Kozasa, T., & Le Breton, G. C. (2007). Signaling through G(alpha)13 switch region I is essential for protease-activated receptor 1-mediated human platelet shape change, aggregation, and secretion. The Journal of Biological Chemistry, 282(14), 10210–10222.PubMed
334.
Calaminus, S. D., Auger, J. M., McCarty, O. J., Wakelam, M. J., Machesky, L. M., & Watson, S. P. (2007). MyosinIIa contractility is required for maintenance of platelet structure during spreading on collagen and contributes to thrombus stability. Journal of Thrombosis and Haemostasis, 5(10), 2136–2145.PubMed
335.
Getz, T. M., Dangelmaier, C. A., Jin, J., Daniel, J. L., & Kunapuli, S. P. (2010). Differential phosphorylation of myosin light chain (Thr)18 and (Ser)19 and functional implications in platelets. Journal of Thrombosis and Haemostasis, 8(10), 2283–2293.PubMedPubMedCentral
336.
Ueda, K., Ohta, Y., & Hosoya, H. (2003). The carboxy-terminal pleckstrin homology domain of ROCK interacts with filamin-A. Biochemical and Biophysical Research Communications, 301(4), 886–890.PubMed
337.
Itoh, K., Hara, T., & Shibata, N. (1992). Diphosphorylation of platelet myosin by myosin light chain kinase. Biochimica et Biophysica Acta, 1133(3), 286–292.PubMed
338.
Signorello, M. G., Giacobbe, E., Passalacqua, M., & Leoncini, G. (2013). The 2-arachidonoylglycerol effect on myosin light chain phosphorylation in human platelets. Biochimie, 95(8), 1620–1628.PubMed
339.
Wraith, K. S., Magwenzi, S., Aburima, A., Wen, Y., Leake, D., & Naseem, K. M. (2013). Oxidized low-density lipoproteins induce rapid platelet activation and shape change through tyrosine kinase and Rho kinase-signaling pathways. Blood, 122(4), 580–589.PubMedPubMedCentral
340.
Leisner, T. M., Liu, M., Jaffer, Z. M., Chernoff, J., & Parise, L. V. (2005). Essential role of CIB1 in regulating PAK1 activation and cell migration. The Journal of Cell Biology, 170(3), 465–476.PubMedPubMedCentral
341.
Pandey, D., Goyal, P., Bamburg, J. R., & Siess, W. (2006). Regulation of LIM-kinase 1 and cofilin in thrombin-stimulated platelets. Blood, 107(2), 575–583.PubMedPubMedCentral
342.
Pandey, D., Goyal, P., & Siess, W. (2007). Lysophosphatidic acid stimulation of platelets rapidly induces Ca2+-dependent dephosphorylation of cofilin that is independent of dense granule secretion and aggregation. Blood Cells, Molecules & Diseases, 38(3), 269–279.
343.
Akbar, H., Shang, X., Perveen, R., Berryman, M., Funk, K., Johnson, J. F., et al. (2011). Gene targeting implicates Cdc42 GTPase in GPVI and non-GPVI mediated platelet filopodia formation, secretion and aggregation. PLoS One, 6(7), e22117.PubMedPubMedCentral
344.
Carpenter, C. L., Tolias, K. F., Couvillon, A. C., & Hartwig, J. H. (1997). Signal transduction pathways involving the small G proteins rac and Cdc42 and phosphoinositide kinases. Advances in Enzyme Regulation, 37, 377–390.PubMed
345.
Egile, C., Loisel, T. P., Laurent, V., Li, R., Pantaloni, D., Sansonetti, P. J., et al. (1999). Activation of the CDC42 effector N-WASP by the Shigella flexneri IcsA protein promotes actin nucleation by Arp2/3 complex and bacterial actin-based motility. The Journal of Cell Biology, 146(6), 1319–1332.PubMedPubMedCentral
346.
Miki, H., Suetsugu, S., & Takenawa, T. (1998). WAVE, a novel WASP-family protein involved in actin reorganization induced by Rac. The EMBO Journal, 17(23), 6932–6941.PubMedPubMedCentral
347.
McCarty, O. J., Larson, M. K., Auger, J. M., Kalia, N., Atkinson, B. T., Pearce, A. C., et al. (2005). Rac1 is essential for platelet lamellipodia formation and aggregate stability under flow. The Journal of Biological Chemistry, 280(47), 39474–39484.PubMedPubMedCentral
348.
Oda, A., Miki, H., Wada, I., Yamaguchi, H., Yamazaki, D., Suetsugu, S., et al. (2005). WAVE/scars in platelets. Blood, 105(8), 3141–3148.PubMed
349.
Coburn, L. A., Damaraju, V. S., Dozic, S., Eskin, S. G., Cruz, M. A., & McIntire, L. V. (2011). GPIbalpha-vWF rolling under shear stress shows differences between type 2B and 2M von Willebrand disease. Biophysical Journal, 100(2), 304–312.PubMedPubMedCentral
350.
Colace, T. V., & Diamond, S. L. (2013). Direct observation of von Willebrand factor elongation and fiber formation on collagen during acute whole blood exposure to pathological flow. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(1), 105–113.PubMedPubMedCentral
351.
Fredrickson, B. J., Dong, J. F., McIntire, L. V., & Lopez, J. A. (1998). Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood, 92(10), 3684–3693.PubMed
352.
Jackson, S. P., Mistry, N., & Yuan, Y. (2000). Platelets and the injured vessel wall—“rolling into action”: focus on glycoprotein Ib/V/IX and the platelet cytoskeleton. Trends in Cardiovascular Medicine, 10(5), 192–197.PubMed
353.
Yago, T., Lou, J., Wu, T., Yang, J., Miner, J. J., Coburn, L., et al. (2008). Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. The Journal of Clinical Investigation, 118(9), 3195–3207.PubMedPubMedCentral
354.
Li, R., & Emsley, J. (2013). The organizing principle of the platelet glycoprotein Ib-IX-V complex. Journal of Thrombosis and Haemostasis, 11(4), 605–614.PubMedPubMedCentral
355.
Clemetson, K. J. (2007). A short history of platelet glycoprotein Ib complex. Thrombosis and Haemostasis, 98(1), 63–68.PubMed
356.
Bernard, J., & Soulier, J. (1948). Sur une nouvelle variété de dystrophie thrombocytaire-hémorragipare congénitale. Semin Hôp Paris, 24, 3217–3223.
357.
Ozaki, Y., Suzuki-Inoue, K., & Inoue, O. (2013). Platelet receptors activated via mulitmerization: glycoprotein VI, GPIb-IX-V, and CLEC-2. Journal of Thrombosis and Haemostasis, 11(Suppl 1), 330–339.PubMed
358.
Canobbio, I., Balduini, C., & Torti, M. (2004). Signalling through the platelet glycoprotein Ib-V-IX complex. Cellular Signalling, 16(12), 1329–1344.PubMed
359.
Gardiner, E. E., Arthur, J. F., Berndt, M. C., & Andrews, R. K. (2005). Role of calmodulin in platelet receptor function. Current Medicinal Chemistry. Cardiovascular and Hematological Agents, 3(4), 283–287.PubMed
360.
Bernardo, A., Ball, C., Nolasco, L., Choi, H., Moake, J. L., & Dong, J. F. (2005). Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. Journal of Thrombosis and Haemostasis, 3(3), 562–570.PubMed
361.
De Ceunynck, K., De Meyer, S. F., & Vanhoorelbeke, K. (2013). Unwinding the von Willebrand factor strings puzzle. Blood, 121(2), 270–277.PubMed
362.
Desch, A., Strozyk, E. A., Bauer, A. T., Huck, V., Niemeyer, V., Wieland, T., et al. (2012). Highly invasive melanoma cells activate the vascular endothelium via an MMP-2/integrin alphavbeta5-induced secretion of VEGF-A. The American Journal of Pathology, 181(2), 693–705.PubMed
363.
Coller, B. S., & Shattil, S. J. (2008). The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood, 112(8), 3011–3025.PubMedPubMedCentral
364.
Kim, C., & Kim, M. C. (2013). Differences in alpha-beta transmembrane domain interactions among integrins enable diverging integrin signaling. Biochemical and Biophysical Research Communications, 436(3), 406–412.PubMed
365.
Kim, C., Lau, T. L., Ulmer, T. S., & Ginsberg, M. H. (2009). Interactions of platelet integrin alphaIIb and beta3 transmembrane domains in mammalian cell membranes and their role in integrin activation. Blood, 113(19), 4747–4753.PubMedPubMedCentral
366.
Shattil, S. J. (2009). The beta3 integrin cytoplasmic tail: protein scaffold and control freak. Journal of Thrombosis and Haemostasis, 7(Suppl 1), 210–213.PubMed
367.
Nurden, A. T., & Caen, J. P. (1974). An abnormal platelet glycoprotein pattern in three cases of Glanzmann’s thrombasthenia. British Journal of Haematology, 28(2), 253–260.PubMed
368.
Phillips, D. R., Jenkins, C. S., Luscher, E. F., & Larrieu, M. (1975). Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes. Nature, 257(5527), 599–600.PubMed
369.
Glanzmann, E. (1918). Hereditare hammorhagische thrombastehnie. Beitr Pathologie Bluplatchen J Kinderkt, 88, 113–141.
370.
Clemetson, K. J. (1995). Platelet activation: signal transduction via membrane receptors. Thrombosis and Haemostasis, 74(1), 111–116.PubMed
371.
Moroi, M., Jung, S. M., Okuma, M., & Shinmyozu, K. (1989). A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. The Journal of Clinical Investigation, 84(5), 1440–1445.PubMedPubMedCentral
372.
Asselin, J., Knight, C. G., Farndale, R. W., Barnes, M. J., & Watson, S. P. (1999). Monomeric (glycine-proline-hydroxyproline)10 repeat sequence is a partial agonist of the platelet collagen receptor glycoprotein VI. The Biochemical Journal, 339(Pt 2), 413–418.PubMedPubMedCentral
373.
Kehrel, B., Wierwille, S., Clemetson, K. J., Anders, O., Steiner, M., Knight, C. G., et al. (1998). Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not. Blood, 91(2), 491–499.PubMed
374.
Zahid, M., Mangin, P., Loyau, S., Hechler, B., Billiald, P., Gachet, C., et al. (2012). The future of glycoprotein VI as an antithrombotic target. Journal of Thrombosis and Haemostasis, 10(12), 2418–2427.PubMed
375.
Bergmeier, W., & Stefanini, L. (2013). Platelet ITAM signaling. Current Opinion in Hematology, 20(5), 445–450.PubMed
376.
Ezumi, Y., Shindoh, K., Tsuji, M., & Takayama, H. (1998). Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets. The Journal of Experimental Medicine, 188(2), 267–276.PubMedPubMedCentral
377.
Watson, S. P., Asazuma, N., Atkinson, B., Berlanga, O., Best, D., Bobe, R., et al. (2001). The role of ITAM- and ITIM-coupled receptors in platelet activation by collagen. Thrombosis and Haemostasis, 86(1), 276–288.PubMed
378.
Navarro-Nunez, L., Langan, S. A., Nash, G. B., & Watson, S. P. (2013). The physiological and pathophysiological roles of platelet CLEC-2. Thrombosis and Haemostasis, 109(6), 991–998.PubMedPubMedCentral
379.
Suzuki-Inoue, K., Fuller, G. L., Garcia, A., Eble, J. A., Pohlmann, S., Inoue, O., et al. (2006). A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood, 107(2), 542–549.PubMed
380.
Suzuki-Inoue, K., Kato, Y., Inoue, O., Kaneko, M. K., Mishima, K., Yatomi, Y., et al. (2007). Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. The Journal of Biological Chemistry, 282(36), 25993–26001.PubMed
381.
Lowe, K. L., Navarro-Nunez, L., & Watson, S. P. (2012). Platelet CLEC-2 and podoplanin in cancer metastasis. Thrombosis Research, 129(Suppl 1), S30–37.PubMed
382.
Ordonez, N. G. (2013). Value of podoplanin as an immunohistochemical marker in tumor diagnosis: a review and update. Applied Immunohistochemistry & Molecular Morphology.
383.
Pula, B., Witkiewicz, W., Dziegiel, P., & Podhorska-Okolow, M. (2013). Significance of podoplanin expression in cancer-associated fibroblasts: a comprehensive review. International Journal of Oncology, 42(6), 1849–1857.PubMed
384.
Takagi, S., Sato, S., Oh-hara, T., Takami, M., Koike, S., Mishima, Y., et al. (2013). Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS One, 8(8), e73609.PubMedPubMedCentral
385.
Watson, A. A., Brown, J., Harlos, K., Eble, J. A., Walter, T. S., & O'Callaghan, C. A. (2007). The crystal structure and mutational binding analysis of the extracellular domain of the platelet-activating receptor CLEC-2. The Journal of Biological Chemistry, 282(5), 3165–3172.PubMed
386.
Watson, A. A., & O'Callaghan, C. A. (2005). Crystallization and X-ray diffraction analysis of human CLEC-2. Acta Crystallographica. Section F, Structural Biology and Crystallization Communications, 61(Pt 12), 1094–1096.PubMedPubMedCentral
387.
Suzuki-Inoue, K., Inoue, O., & Ozaki, Y. (2011). Novel platelet activation receptor CLEC-2: from discovery to prospects. Journal of Thrombosis and Haemostasis, 9(Suppl 1), 44–55.PubMed
388.
Suzuki-Inoue, K., Inoue, O., & Ozaki, Y. (2011). The novel platelet activation receptor CLEC-2. Platelets, 22(5), 380–384.PubMed
389.
Watson, A. A., & O'Callaghan, C. A. (2011). Molecular analysis of the interaction of the snake venom rhodocytin with the platelet receptor CLEC-2. Toxins (Basel), 3(8), 991–1003.
390.
Johnston, G. I., Cook, R. G., & McEver, R. P. (1989). Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation. Cell, 56(6), 1033–1044.PubMed
391.
Stenberg, P. E., McEver, R. P., Shuman, M. A., Jacques, Y. V., & Bainton, D. F. (1985). A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. The Journal of Cell Biology, 101(3), 880–886.PubMed
392.
Zarbock, A., Muller, H., Kuwano, Y., & Ley, K. (2009). PSGL-1-dependent myeloid leukocyte activation. Journal of Leukocyte Biology, 86(5), 1119–1124.PubMed
393.
Picker, L. J., Warnock, R. A., Burns, A. R., Doerschuk, C. M., Berg, E. L., & Butcher, E. C. (1991). The neutrophil selectin LECAM-1 presents carbohydrate ligands to the vascular selectins ELAM-1 and GMP-140. Cell, 66(5), 921–933.PubMed
394.
Polley, M. J., Phillips, M. L., Wayner, E., Nudelman, E., Singhal, A. K., Hakomori, S., et al. (1991). CD62 and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) recognize the same carbohydrate ligand, sialyl-Lewis x. Proceedings of the National Academy of Sciences of the United States of America, 88(14), 6224–6228.PubMedPubMedCentral
395.
Foxall, C., Watson, S. R., Dowbenko, D., Fennie, C., Lasky, L. A., Kiso, M., et al. (1992). The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis(x) oligosaccharide. The Journal of Cell Biology, 117(4), 895–902.PubMed
396.
Habets, K. L., Huizinga, T. W., & Toes, R. E. (2013). Platelets and autoimmunity. European Journal of Clinical Investigation, 43(7), 746–757.PubMed
397.
Kazmi, R. S., Cooper, A. J., & Lwaleed, B. A. (2011). Platelet function in pre-eclampsia. Seminars in Thrombosis and Hemostasis, 37(2), 131–136.PubMed
398.
Nurden, A. T. (2011). Platelets, inflammation and tissue regeneration. Thrombosis and Haemostasis, 105(Suppl 1), S13–33.PubMed
399.
Ozeki, Y., Ito, H., Nagamura, Y., Unemi, F., & Igawa, T. (1998). 12(S)-HETE plays a role as a mediator of expression of platelet CD62 (P-selectin). Platelets, 9(5), 297–302.PubMed
400.
Borsig, L. (2008). The role of platelet activation in tumor metastasis. Expert Review of Anticancer Therapy, 8(8), 1247–1255.PubMed
401.
Dammacco, F., Vacca, A., Procaccio, P., Ria, R., Marech, I., & Racanelli, V. (2013). Cancer-related coagulopathy (Trousseau’s syndrome): review of the literature and experience of a single center of internal medicine. Clinical and Experimental Medicine, 13(2), 85–97.PubMed
402.
Kyriazi, V., & Theodoulou, E. (2013). Assessing the risk and prognosis of thrombotic complications in cancer patients. Archives of Pathology & Laboratory Medicine, 137(9), 1286–1295.
403.
McEver, R. P. (1997). Selectin-carbohydrate interactions during inflammation and metastasis. Glycoconjugate Journal, 14(5), 585–591.PubMed
404.
Erpenbeck, L., & Schon, M. P. (2010). Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood, 115(17), 3427–3436.PubMedPubMedCentral
405.
Gay, L. J., & Felding-Habermann, B. (2011). Platelets alter tumor cell attributes to propel metastasis: programming in transit. Cancer Cell, 20(5), 553–554.PubMed
406.
Gay, L. J., & Felding-Habermann, B. (2011). Contribution of platelets to tumour metastasis. Nature Reviews. Cancer, 11(2), 123–134.PubMed
407.
Koziak, K., Sevigny, J., Robson, S. C., Siegel, J. B., & Kaczmarek, E. (1999). Analysis of CD39/ATP diphosphohydrolase (ATPDase) expression in endothelial cells, platelets and leukocytes. Thrombosis and Haemostasis, 82(5), 1538–1544.PubMed
408.
Zimmermann, H. (1999). Nucleotides and cd39: principal modulatory players in hemostasis and thrombosis. Nature Medicine, 5(9), 987–988.PubMed
409.
Feng, D., Nagy, J. A., Pyne, K., Dvorak, H. F., & Dvorak, A. M. (1998). Platelets exit venules by a transcellular pathway at sites of F-met peptide-induced acute inflammation in guinea pigs. International Archives of Allergy and Immunology, 116(3), 188–195.PubMed
410.
Gawaz, M., & Vogel, S. (2013). Platelets in tissue repair: control of apoptosis and interactions with regenerative cells. Blood, 122(15), 2550–2554.PubMed
411.
Lowenhaupt, R. W., Glueck, H. I., Miller, M. A., & Kline, D. L. (1977). Factors which influence blood platelet migration. The Journal of Laboratory and Clinical Medicine, 90(1), 37–45.PubMed
412.
Nathan, P. (1973). The migration of human platelets in vitro. Thrombosis et Diathesis Haemorrhagica, 30(1), 173–177.PubMed
413.
Schmidt, E. M., Munzer, P., Borst, O., Kraemer, B. F., Schmid, E., Urban, B., et al. (2011). Ion channels in the regulation of platelet migration. Biochemical and Biophysical Research Communications, 415(1), 54–60.PubMed
414.
Aleman, M. M., Gardiner, C., Harrison, P., & Wolberg, A. S. (2011). Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. Journal of Thrombosis and Haemostasis, 9(11), 2251–2261.PubMedPubMedCentral
415.
Fisher, B., & Fisher, E. R. (1966). Transmigration of lymph nodes by tumor cells. Science, 152(3727), 1397–1398.PubMed
416.
Sleeman, J. P., Cady, B., & Pantel, K. (2012). The connectivity of lymphogenous and hematogenous tumor cell dissemination: biological insights and clinical implications. Clinical & Experimental Metastasis, 29(7), 737–746.
417.
Sleeman, J. P., Nazarenko, I., & Thiele, W. (2011). Do all roads lead to Rome? Routes to metastasis development. International Journal of Cancer, 128(11), 2511–2526.
418.
Baker, M., Reynolds, L. E., Robinson, S. D., Lees, D. M., Parsons, M., Elia, G., et al. (2013). Stromal Claudin14-heterozygosity, but not deletion, increases tumour blood leakage without affecting tumour growth. PLoS One, 8(5), e62516.PubMedPubMedCentral
419.
Brown, P. (2005). Lymphatic system: unlocking the drains. Nature, 436(7050), 456–458.PubMed
420.
Kushner, E. J., & Bautch, V. L. (2013). Building blood vessels in development and disease. Current Opinion in Hematology, 20(3), 231–236.PubMed
421.
Mueller, B. M., Reisfeld, R. A., Edgington, T. S., & Ruf, W. (1992). Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proceedings of the National Academy of Sciences of the United States of America, 89(24), 11832–11836.PubMedPubMedCentral
422.
Bouvenot, G., Escande, M., Xeridat, B., Simonin, G., Boucoiran, J., & Delboy, C. (1977). Thrombocytosis and cancer. Apropos of a chronological series of 100 patients. La Semaine des Hôpitaux, 53(36), 1921–1925.PubMed
423.
Stone, R. L., Nick, A. M., McNeish, I. A., Balkwill, F., Han, H. D., Bottsford-Miller, J., et al. (2012). Paraneoplastic thrombocytosis in ovarian cancer. The New England Journal of Medicine, 366(7), 610–618.PubMedPubMedCentral
424.
Rank, A., Liebhardt, S., Zwirner, J., Burges, A., Nieuwland, R., & Toth, B. (2012). Circulating microparticles in patients with benign and malignant ovarian tumors. Anticancer Research, 32(5), 2009–2014.PubMed
425.
Nieuwland, R., Berckmans, R. J., Rotteveel-Eijkman, R. C., Maquelin, K. N., Roozendaal, K. J., Jansen, P. G., et al. (1997). Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation, 96(10), 3534–3541.PubMed
426.
van Doormaal, F., Kleinjan, A., Berckmans, R. J., Mackman, N., Manly, D., Kamphuisen, P. W., et al. (2012). Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study. Thrombosis and Haemostasis, 108(1), 160–165.PubMed
427.
Rank, A., Nieuwland, R., Roesner, S., Nikolajek, K., Hiller, E., & Toth, B. (2012). Climacteric lowers plasma levels of platelet-derived microparticles: a pilot study in pre- versus postmenopausal women. Acta Haematologica, 128(1), 53–59.PubMed
428.
Hunter, M. P., Ismail, N., Zhang, X., Aguda, B. D., Lee, E. J., Yu, L., et al. (2008). Detection of microRNA expression in human peripheral blood microvesicles. PLoS One, 3(11), e3694.PubMedPubMedCentral
429.
Fidler, I. J. (1978). Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Research, 38(9), 2651–2660.PubMed
430.
Talmadge, J. E., & Fidler, I. J. (2010). AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Research, 70(14), 5649–5669.PubMed
431.
Bidard, F. C., Pierga, J. Y., Soria, J. C., & Thiery, J. P. (2013). Translating metastasis-related biomarkers to the clinic—progress and pitfalls. Nature Reviews. Clinical Oncology, 10(3), 169–179.PubMed
432.
Morello, M., Minciacchi, V. R., de Candia, P., Yang, J., Posadas, E., Kim, H., et al. (2013). Large oncosomes mediate intercellular transfer of functional microRNA. Cell Cycle, 12(22), 3526–3536.PubMedPubMedCentral
433.
Uchide, K., Sakon, M., Ariyoshi, H., Nakamori, S., Tokunaga, M., & Monden, M. (2007). Cancer cells cause vascular endothelial cell (vEC) retraction via 12(S)HETE secretion; the possible role of cancer cell derived microparticle. Annals of Surgical Oncology, 14(2), 862–868.PubMed
434.
van der Pol, E., Boing, A. N., Harrison, P., Sturk, A., & Nieuwland, R. (2012). Classification, functions, and clinical relevance of extracellular vesicles. Pharmacological Reviews, 64(3), 676–705.PubMed
435.
Williams, S. C. (2013). Circulating tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 110(13), 4861.PubMedPubMedCentral
436.
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., et al. (2011). Tumour evolution inferred by single-cell sequencing. Nature, 472(7341), 90–94.PubMed
437.
Green, D. L., & Karpatkin, S. (2009). Effect of cancer on platelets. Cancer Treatment and Research, 148, 17–30.PubMed
438.
Pearlstein, E., Salk, P. L., Yogeeswaran, G., & Karpatkin, S. (1980). Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialylation in 10 metastatic-variant derivatives of a rat renal sarcoma cell line. Proceedings of the National Academy of Sciences of the United States of America, 77(7), 4336–4339.PubMedPubMedCentral
439.
Grignani, G., Pacchiarini, L., Almasio, P., Pagliarino, M., Gamba, G., Rizzo, S. C., et al. (1986). Characterization of the platelet-aggregating activity of cancer cells with different metastatic potential. International Journal of Cancer, 38(2), 237–244.
440.
Menter, D. G., Onoda, J. M., Moilanen, D., Sloane, B. F., Taylor, J. D., & Honn, K. V. (1987). Inhibition by prostacyclin of the tumor cell-induced platelet release reaction and platelet aggregation. Journal of the National Cancer Institute, 78(5), 961–969.PubMed
441.
Lee, J. J., Yu, J. Y., Lee, J. H., Zhang, W. Y., Kim, T. J., Myung, C. S., et al. (2010). The protective effects of paclitaxel on platelet aggregation through the inhibition of thromboxane A2 synthase. Archives of Pharmacal Research, 33(3), 387–394.PubMed
442.
de Leval, X., Benoit, V., Delarge, J., Julemont, F., Masereel, B., Pirotte, B., et al. (2003). Pharmacological evaluation of the novel thromboxane modulator BM-567 (II/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 68(1), 55–59.PubMed
443.
Pacchiarini, L., Zucchella, M., Milanesi, G., Tacconi, F., Bonomi, E., Canevari, A., et al. (1991). Thromboxane production by platelets during tumor cell-induced platelet activation. Invasion & Metastasis, 11(2), 102–109.
444.
Tzanakakis, G. N., Krambovitis, E., Tsatsakis, A. M., & Vezeridis, M. P. (2002). The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis. International Journal of Gastrointestinal Cancer, 32(1), 23–30.PubMed
445.
Honn, K. V., Cicone, B., & Skoff, A. (1981). Prostacyclin: a potent antimetastatic agent. Science, 212(4500), 1270–1272.PubMed
446.
Menter, D. G., Schilsky, R. L., & DuBois, R. N. (2010). Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clinical Cancer Research, 16(5), 1384–1390.PubMed
447.
Kanazawa, S., Yamaguchi, K., Kinoshita, Y., Muramatsu, M., Komiyama, Y., & Nomura, S. (2005). Gefitinib affects functions of platelets and blood vessels via changes in prostanoids balance. Clinical and Applied Thrombosis/Hemostasis, 11(4), 429–434.PubMed
448.
Gordon, S. G., & Chelladurai, M. (1992). Non-tissue factor procoagulants in cancer cells. Cancer Metastasis Reviews, 11(3–4), 267–282.PubMed
449.
Jurasz, P., Alonso-Escolano, D., & Radomski, M. W. (2004). Platelet–cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. British Journal of Pharmacology, 143(7), 819–826.PubMedPubMedCentral
450.
Schaffner, F., & Ruf, W. (2009). Tissue factor and PAR2 signaling in the tumor microenvironment. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]. Arteriosclerosis Thrombosis and Vascular Biology, 29(12), 1999–2004.
451.
Kirwan, C. C., McDowell, G., McCollum, C. N., Kumar, S., & Byrne, G. J. (2008). Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. British Journal of Cancer, 99(7), 1000–1006.PubMedPubMedCentral
452.
Levine, M. N. (2007). Adjuvant therapy and thrombosis: how to avoid the problem? Breast, 16(Suppl 2), S169–174.PubMed
453.
Starakis, I., Koutras, A., & Mazokopakis, E. E. (2010). Drug-induced thromboembolic events in patients with malignancy. Cardiovascular & Hematological Disorders Drug Targets, 10(2), 94–102.
454.
Anand, M., & Brat, D. J. (2012). Oncogenic regulation of tissue factor and thrombosis in cancer. Thrombosis Research, 129(Suppl 1), S46–49.PubMed
455.
Falanga, A., Consonni, R., Marchetti, M., Locatelli, G., Garattini, E., Passerini, C. G., et al. (1998). Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood, 92(1), 143–151.PubMed
456.
Ogiichi, T., Hirashima, Y., Nakamura, S., Endo, S., Kurimoto, M., & Takaku, A. (2000). Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation. Journal of Neuro-Oncology, 46(1), 1–9.PubMed
457.
Belloc, C., Lu, H., Soria, C., Fridman, R., Legrand, Y., & Menashi, S. (1995). The effect of platelets on invasiveness and protease production of human mammary tumor cells. International Journal of Cancer, 60(3), 413–417.
458.
Deryugina, E. I., Bourdon, M. A., Jungwirth, K., Smith, J. W., & Strongin, A. Y. (2000). Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. International Journal of Cancer, 86(1), 15–23.
459.
Jurasz, P., North, S., Venner, P., & Radomski, M. W. (2003). Matrix metalloproteinase-2 contributes to increased platelet reactivity in patients with metastatic prostate cancer: a preliminary study. Thrombosis Research, 112(1–2), 59–64.PubMed
460.
Alonso-Escolano, D., Strongin, A. Y., Chung, A. W., Deryugina, E. I., & Radomski, M. W. (2004). Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. British Journal of Pharmacology, 141(2), 241–252.PubMedPubMedCentral
461.
Dilly, A. K., Ekambaram, P., Guo, Y., Cai, Y., Tucker, S. C., Fridman, R., et al. (2013). Platelet-type 12-lipoxygenase induces MMP9 expression and cellular invasion via activation of PI3K/Akt/NF-kappaB. International Journal of Cancer, 133(8), 1784–1791.
462.
Lindenmeyer, F., Legrand, Y., & Menashi, S. (1997). Upregulation of MMP-9 expression in MDA-MB231 tumor cells by platelet granular membrane. FEBS Letters, 418(1–2), 19–22.PubMed
463.
Radomski, A., Jurasz, P., Sanders, E. J., Overall, C. M., Bigg, H. F., Edwards, D. R., et al. (2002). Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets. British Journal of Pharmacology, 137(8), 1330–1338.PubMedPubMedCentral
464.
Zhong, J., Gencay, M. M., Bubendorf, L., Burgess, J. K., Parson, H., Robinson, B. W., et al. (2006). ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells. Journal of Cellular Physiology, 207(2), 540–552.PubMed
465.
Axelrad, T. W., Deo, D. D., Ottino, P., Van Kirk, J., Bazan, N. G., Bazan, H. E., et al. (2004). Platelet-activating factor (PAF) induces activation of matrix metalloproteinase 2 activity and vascular endothelial cell invasion and migration. The FASEB Journal, 18(3), 568–570.
466.
Melnikova, V. O., Mourad-Zeidan, A. A., Lev, D. C., & Bar-Eli, M. (2006). Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. The Journal of Biological Chemistry, 281(5), 2911–2922.PubMed
467.
Oleksowicz, L., Mrowiec, Z., Schwartz, E., Khorshidi, M., Dutcher, J. P., & Puszkin, E. (1995). Characterization of tumor-induced platelet aggregation: the role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells. Thrombosis Research, 79(3), 261–274.PubMed
468.
Jurasz, P., Stewart, M. W., Radomski, A., Khadour, F., Duszyk, M., & Radomski, M. W. (2001). Role of von Willebrand factor in tumour cell-induced platelet aggregation: differential regulation by NO and prostacyclin. British Journal of Pharmacology, 134(5), 1104–1112.PubMedPubMedCentral
469.
Karpatkin, S., Pearlstein, E., Ambrogio, C., & Coller, B. S. (1988). Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. The Journal of Clinical Investigation, 81(4), 1012–1019.PubMedPubMedCentral
470.
Chopra, H., Timar, J., Rong, X., Grossi, I. M., Hatfield, J. S., Fligiel, S. E., et al. (1992). Is there a role for the tumor cell integrin alpha IIb beta 3 and cytoskeleton in tumor cell-platelet interaction? Clinical & Experimental Metastasis, 10(2), 125–137.
471.
Timar, J., Trikha, M., Szekeres, K., Bazaz, R., & Honn, K. (1998). Expression and function of the high affinity alphaIIbbeta3 integrin in murine melanoma cells. Clinical & Experimental Metastasis, 16(5), 437–445.
472.
Trikha, M., Timar, J., Lundy, S. K., Szekeres, K., Cai, Y., Porter, A. T., et al. (1997). The high affinity alphaIIb beta3 integrin is involved in invasion of human melanoma cells. Cancer Research, 57(12), 2522–2528.PubMed
473.
Trikha, M., Timar, J., Zacharek, A., Nemeth, J. A., Cai, Y., Dome, B., et al. (2002). Role for beta3 integrins in human melanoma growth and survival. International Journal of Cancer, 101(2), 156–167.
474.
Felding-Habermann, B., O'Toole, T. E., Smith, J. W., Fransvea, E., Ruggeri, Z. M., Ginsberg, M. H., et al. (2001). Integrin activation controls metastasis in human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 98(4), 1853–1858.PubMedPubMedCentral
475.
Iwamura, T., Caffrey, T. C., Kitamura, N., Yamanari, H., Setoguchi, T., & Hollingsworth, M. A. (1997). P-selectin expression in a metastatic pancreatic tumor cell line (SUIT-2). Cancer Research, 57(6), 1206–1212.PubMed
476.
Kim, Y. J., Borsig, L., Varki, N. M., & Varki, A. (1998). P-selectin deficiency attenuates tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 95(16), 9325–9330.PubMedPubMedCentral
477.
Pottratz, S. T., Hall, T. D., Scribner, W. M., Jayaram, H. N., & Natarajan, V. (1996). P-selectin-mediated attachment of small cell lung carcinoma to endothelial cells. The American Journal of Physiology, 271(6 Pt 1), L918–923.PubMed
478.
Stone, J. P., & Wagner, D. D. (1993). P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer. The Journal of Clinical Investigation, 92(2), 804–813.PubMedPubMedCentral
479.
Varki, A., & Varki, N. M. (2001). P-selectin, carcinoma metastasis and heparin: novel mechanistic connections with therapeutic implications. Brazilian Journal of Medical and Biological Research, 34(6), 711–717.PubMed
480.
Ulrych, T., Bohm, A., Polzin, A., Daum, G., Nusing, R. M., Geisslinger, G., et al. (2011). Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation. Journal of Thrombosis and Haemostasis, 9(4), 790–798.PubMed
481.
Boucharaba, A., Serre, C. M., Gres, S., Saulnier-Blache, J. S., Bordet, J. C., Guglielmi, J., et al. (2004). Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. The Journal of Clinical Investigation, 114(12), 1714–1725.PubMedPubMedCentral
482.
Goschnick, M. W., & Jackson, D. E. (2007). Tetraspanins-structural and signalling scaffolds that regulate platelet function. Mini Reviews in Medicinal Chemistry, 7(12), 1248–1254.PubMed
483.
Haining, E. J., Yang, J., & Tomlinson, M. G. (2011). Tetraspanin microdomains: fine-tuning platelet function. Biochemical Society Transactions, 39(2), 518–523.PubMed
484.
Protty, M. B., Watkins, N. A., Colombo, D., Thomas, S. G., Heath, V. L., Herbert, J. M., et al. (2009). Identification of Tspan9 as a novel platelet tetraspanin and the collagen receptor GPVI as a component of tetraspanin microdomains. The Biochemical Journal, 417(1), 391–400.PubMedPubMedCentral
485.
Sordat, I., Decraene, C., Silvestre, T., Petermann, O., Auffray, C., Pietu, G., et al. (2002). Complementary DNA arrays identify CD63 tetraspanin and alpha3 integrin chain as differentially expressed in low and high metastatic human colon carcinoma cells. Laboratory Investigation, 82(12), 1715–1724.PubMed
486.
Israels, S. J., McMillan, E. M., Robertson, C., Singhory, S., & McNicol, A. (1996). The lysosomal granule membrane protein, LAMP-2, is also present in platelet dense granule membranes. Thrombosis and Haemostasis, 75(4), 623–629.PubMed
487.
Vanags, D. M., Rodgers, S. E., Duncan, E. M., Lloyd, J. V., & Bochner, F. (1992). Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline. British Journal of Pharmacology, 106(4), 917–923.PubMedPubMedCentral
488.
Billroth, T. (1878). Lectures on surgical pathology and therapeutics, a handbook for students and practitioners (vol. II). London: The New Sydenham Society.
489.
Baserga, R., & Saffiotti, U. (1955). Experimental studies on histogenesis of blood-borne metastases. AMA Archives of Pathology, 59(1), 26–34.PubMed
490.
Jones, D. S., Wallace, A. C., & Fraser, E. E. (1971). Sequence of events in experimental metastases of Walker 256 tumor: light, immunofluorescent, and electron microscopic observations. Journal of the National Cancer Institute, 46(3), 493–504.PubMed
491.
Chew, E. C., & Wallace, A. C. (1976). Demonstration of fibrin in early stages of experimental metastases. Cancer Research, 36(6), 1904–1909.PubMed
492.
Warren, B. A., & Vales, O. (1972). The release of vesicles from platelets following adhesion to vessel walls in vitro. British Journal of Experimental Pathology, 53(2), 206–215.PubMedPubMedCentral
493.
Warren, B. A. (1976). Some aspects of blood borne tumour emboli associated with thrombosis. Zeitschrift für Krebsforschung und Klinische Onkologie. Cancer Research and Clinical Oncology, 87(1), 1–15.PubMed
494.
Banfalvi, G. (2008). Cell cycle synchronization of animal cells and nuclei by centrifugal elutriation. Nature Protocols, 3(4), 663–673.PubMed
495.
Oleksowicz, L., & Dutcher, J. P. (1995). Adhesive receptors expressed by tumor cells and platelets: novel targets for therapeutic anti-metastatic strategies. Medical Oncology, 12(2), 95–102.PubMed
496.
Lonsdorf, A. S., Kramer, B. F., Fahrleitner, M., Schonberger, T., Gnerlich, S., Ring, S., et al. (2012). Engagement of alphaIIbbeta3 (GPIIb/IIIa) with alphanubeta3 integrin mediates interaction of melanoma cells with platelets: a connection to hematogenous metastasis. The Journal of Biological Chemistry, 287(3), 2168–2178.PubMedPubMedCentral
497.
Timp, J. F., Braekkan, S. K., Versteeg, H. H., & Cannegieter, S. C. (2013). Epidemiology of cancer-associated venous thrombosis. Blood, 122(10), 1712–1723.PubMed
498.
Beleva, E., & Grudeva-Popova, J. (2013). From Virchow’s triad to metastasis: circulating hemostatic factors as predictors of risk for metastasis in solid tumors. Journal of BUON, 18(1), 25–33.PubMed
499.
Lee, A. Y., & Peterson, E. A. (2013). Treatment of cancer-associated thrombosis. Blood, 122(14), 2310–2317.PubMed
500.
Barsam, S. J., Patel, R., & Arya, R. (2013). Anticoagulation for prevention and treatment of cancer-related venous thromboembolism. British Journal of Haematology, 161(6), 764–777.PubMed
501.
Rajalingham, S., & Das, S. (2012). Antagonizing IL-6 in ankylosing spondylitis: a short review. Inflammation & Allergy Drug Targets, 11(4), 262–265.
502.
Schoels, M. M., van der Heijde, D., Breedveld, F. C., Burmester, G. R., Dougados, M., Emery, P., et al. (2013). Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Annals of the Rheumatic Diseases, 72(4), 583–589.PubMedPubMedCentral
503.
Homeida, S., Ebdon, C., Batty, P., Jackson, B., Kolade, S., Bateman, C., et al. (2012). New thrombopoietin receptor agonists for platelet disorders. Drugs of Today (Barcelona, Spain), 48(4), 293–301.
504.
Kuter, D. J. (2009). Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annual Review of Medicine, 60, 193–206.PubMed
505.
Hinson, R. M., Williams, J. A., & Shacter, E. (1996). Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proceedings of the National Academy of Sciences of the United States of America, 93(10), 4885–4890.PubMedPubMedCentral
506.
Abnet, C. C., Freedman, N. D., Kamangar, F., Leitzmann, M. F., Hollenbeck, A. R., & Schatzkin, A. (2009). Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. British Journal of Cancer, 100(3), 551–557.PubMedPubMedCentral
507.
Bosetti, C., Gallus, S., & La Vecchia, C. (2006). Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes & Control, 17(7), 871–888.
508.
Cole, B. F., Logan, R. F., Halabi, S., Benamouzig, R., Sandler, R. S., Grainge, M. J., et al. (2009). Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. Journal of the National Cancer Institute, 101(4), 256–266.PubMed
509.
Harris, R. E. (2009). Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology, 17(2), 55–67.PubMed
510.
Jafari, S., Etminan, M., & Afshar, K. (2009). Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis. Canadian Urological Association Journal, 3(4), 323–330.PubMedPubMedCentral
511.
Khuder, S. A., Herial, N. A., Mutgi, A. B., & Federman, D. J. (2005). Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis. Chest, 127(3), 748–754.PubMed
512.
Takkouche, B., Regueira-Mendez, C., & Etminan, M. (2008). Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Journal of the National Cancer Institute, 100(20), 1439–1447.PubMed
513.
Chan, A. T., Giovannucci, E. L., Meyerhardt, J. A., Schernhammer, E. S., Curhan, G. C., & Fuchs, C. S. (2005). Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA, 294(8), 914–923.PubMedPubMedCentral
514.
Chan, A. T., Zauber, A. G., Hsu, M., Breazna, A., Hunter, D. J., Rosenstein, R. B., et al. (2009). Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology. doi:10.​1053/​j.​gastro.​2009.​02.​045.
515.
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., et al. (2003). A randomized trial of aspirin to prevent colorectal adenomas. The New England Journal of Medicine, 348(10), 891–899.PubMed
516.
Gallicchio, L., McSorley, M. A., Newschaffer, C. J., Thuita, L. W., Huang, H. Y., Hoffman, S. C., et al. (2006). Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer, 106(7), 1443–1452.PubMed
517.
Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., et al. (2003). A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. The New England Journal of Medicine, 348(10), 883–890.PubMed
518.
Shen, J., Gammon, M. D., Terry, M. B., Teitelbaum, S. L., Neugut, A. I., & Santella, R. M. (2006). Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Research, 8(6), R71.PubMedPubMedCentral
519.
Slatore, C. G., Au, D. H., Littman, A. J., Satia, J. A., & White, E. (2009). Association of nonsteroidal anti-inflammatory drugs with lung cancer: results from a large cohort study. Cancer Epidemiology, Biomarkers & Prevention, 18(4), 1203–1207.
520.
Van Dyke, A. L., Cote, M. L., Prysak, G., Claeys, G. B., Wenzlaff, A. S., & Schwartz, A. G. (2008). Regular adult aspirin use decreases the risk of non-small cell lung cancer among women. Cancer Epidemiology, Biomarkers & Prevention, 17(1), 148–157.
521.
Cuzick, J., Otto, F., Baron, J. A., Brown, P. H., Burn, J., Greenwald, P., et al. (2009). Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. The Lancet Oncology, 10(5), 501–507.PubMed
522.
Arber, N., Eagle, C. J., Spicak, J., Racz, I., Dite, P., Hajer, J., et al. (2006). Celecoxib for the prevention of colorectal adenomatous polyps. The New England Journal of Medicine, 355(9), 885–895.PubMed
523.
Baron, J. A., Sandler, R. S., Bresalier, R. S., Lanas, A., Morton, D. G., Riddell, R., et al. (2008). Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet, 372(9651), 1756–1764.PubMed
524.
Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Breazna, A., Kim, K., et al. (2009). Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prevention Research, 2(4), 310–321.PubMedPubMedCentral
525.
Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Solomon, S. D., Kim, K., et al. (2006). Celecoxib for the prevention of sporadic colorectal adenomas. The New England Journal of Medicine, 355(9), 873–884.PubMed
526.
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., et al. (2005). Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. The New England Journal of Medicine, 352(11), 1092–1102.PubMed
527.
Harris, R. E., Beebe-Donk, J., & Alshafie, G. A. (2007). Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. International Journal of Biological Sciences, 3(5), 328–334.PubMedPubMedCentral
528.
Pruthi, R. S., Derksen, J. E., Moore, D., Carson, C. C., Grigson, G., Watkins, C., et al. (2006). Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clinical Cancer Research, 12(7 Pt 1), 2172–2177.PubMed
529.
Dovizio, M., Maier, T. J., Alberti, S., Di Francesco, L., Marcantoni, E., Munch, G., et al. (2013). Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. Molecular Pharmacology, 84(1), 25–40.PubMed
530.
Konya, V., Marsche, G., Schuligoi, R., & Heinemann, A. (2013). E-type prostanoid receptor 4 (EP4) in disease and therapy. Pharmacology & Therapeutics, 138(3), 485–502.
531.
Norberg, J. K., Sells, E., Chang, H. H., Alla, S. R., Zhang, S., & Meuillet, E. J. (2013). Targeting inflammation: multiple innovative ways to reduce prostaglandin E2. Pharmaceutical Patent Analyst, 2(2), 265–288.PubMed
Metadata
Title
Platelets and cancer: a casual or causal relationship: revisited
Authors
David G. Menter
Stephanie C. Tucker
Scott Kopetz
Anil K. Sood
John D. Crissman
Kenneth V. Honn
Publication date
01-03-2014
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2014
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-014-9498-0

Other articles of this Issue 1/2014

Cancer and Metastasis Reviews 1/2014 Go to the issue

Clinical

Why anti-Bcl-2 clinical trials fail: a solution

Clinical

Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside

EditorialNotes

Gastroenteropancreatic neuroendocrine tumors: current perspectives and future challenges

NON-THEMATIC REVIEW

Oxygen regulates molecular mechanisms of cancer progression and metastasis

NON-THEMATIC REVIEW

Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R’s through dietary manipulation

OriginalPaper

Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits